{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:44:16Z","timestamp":1792788256845,"version":"4.5.0"},"reference-count":317,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["32401087"],"award-info":[{"award-number":["32401087"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82202989"],"award-info":[{"award-number":["No. 82202989"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Sichuan Science and Technology Program","award":["2023NSFSC1742"],"award-info":[{"award-number":["2023NSFSC1742"]}]},{"name":"Sichuan Province Science and Technology Activities Funding for Returned Overseas Scholars"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-024-01628-4","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T04:41:27Z","timestamp":1732768887000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Personalized nanovaccines for treating solid cancer metastases"],"prefix":"10.1186","volume":"17","author":[{"given":"Tang","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jirui","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guowei","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"key":"1628_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41392-020-0134-x","volume":"5","author":"J Fares","year":"2020","unstructured":"Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther. 2020;5:28.","journal-title":"Signal Transduct Target Ther"},{"key":"1628_CR2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12943-019-0961-y","volume":"18","author":"Z Liao","year":"2019","unstructured":"Liao Z, Chua D, Tan NS. Reactive oxygen species: a volatile driver of field cancerization and metastasis. Mol Cancer. 2019;18:65.","journal-title":"Mol Cancer"},{"key":"1628_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.semcancer.2022.10.006","volume":"87","author":"M Castaneda","year":"2022","unstructured":"Castaneda M, den Hollander P, Kuburich NA, Rosen JM, Mani SA. Mechanisms of cancer metastasis. Semin Cancer Biol. 2022;87:17\u201331.","journal-title":"Semin Cancer Biol"},{"key":"1628_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41591-020-01195-4","volume":"27","author":"K Ganesh","year":"2021","unstructured":"Ganesh K, Massagu\u00e9 J. Targeting metastatic cancer. Nat Med. 2021;27:34\u201344.","journal-title":"Nat Med"},{"issue":"6","key":"1628_CR5","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.ccell.2024.05.004","volume":"42","author":"CS McGinnis","year":"2024","unstructured":"McGinnis CS, Miao Z, Superville D, Yao W, Goga A, Reticker-Flynn NE, Winkler J, Satpathy AT. The temporal progression of lung immune remodeling during breast cancer metastasis. Cancer Cell. 2024;42(6):1018-1031.e6. https:\/\/doi.org\/10.1016\/j.ccell.2024.05.004.","journal-title":"Cancer Cell"},{"key":"1628_CR6","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1038\/s41590-024-01960-4","volume":"25","author":"NM Haynes","year":"2024","unstructured":"Haynes NM, Chadwick TB, Parker BS. The complexity of immune evasion mechanisms throughout the metastatic cascade. Nat Immunol. 2024;25:1793\u2013808.","journal-title":"Nat Immunol"},{"key":"1628_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201803322","volume":"31","author":"H Phuengkham","year":"2019","unstructured":"Phuengkham H, Ren L, Shin IW, Lim YT. Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy. Adv Mater. 2019;31: e1803322.","journal-title":"Adv Mater"},{"key":"1628_CR8","first-page":"2787","volume":"136","author":"L Zhu","year":"2023","unstructured":"Zhu L, Wu J, Gao H, Wang T, Xiao G, Hu C, Lin Q, Zhou Q. Tumor immune microenvironment-modulated nanostrategy for the treatment of lung cancer metastasis. Chin Med J (Engl). 2023;136:2787\u2013801.","journal-title":"Chin Med J (Engl)"},{"key":"1628_CR9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40164-024-00539-x","volume":"13","author":"Y Yin","year":"2024","unstructured":"Yin Y, Feng W, Chen J, Chen X, Wang G, Wang S, Xu X, Nie Y, Fan D, Wu K, Xia L. Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside. Exp Hematol Oncol. 2024;13:72.","journal-title":"Exp Hematol Oncol"},{"key":"1628_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201904156","volume":"31","author":"P Zhang","year":"2019","unstructured":"Zhang P, Zhai Y, Cai Y, Zhao Y, Li Y. Nanomedicine-based immunotherapy for the treatment of cancer metastasis. Adv Mater. 2019;31: e1904156.","journal-title":"Adv Mater"},{"key":"1628_CR11","doi-asserted-by":"publisher","first-page":"6250","DOI":"10.1039\/C6CS00458J","volume":"45","author":"C Liang","year":"2016","unstructured":"Liang C, Xu L, Song G, Liu Z. Emerging nanomedicine approaches fighting tumor metastasis: animal models, metastasis-targeted drug delivery, phototherapy, and immunotherapy. Chem Soc Rev. 2016;45:6250\u201369.","journal-title":"Chem Soc Rev"},{"key":"1628_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202103790","volume":"34","author":"J Liu","year":"2022","unstructured":"Liu J, Liew SS, Wang J, Pu K. Bioinspired and Biomimetic Delivery Platforms for Cancer Vaccines. Adv Mater. 2022;34: e2103790.","journal-title":"Adv Mater"},{"key":"1628_CR13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40425-015-0093-x","volume":"3","author":"AC Tan","year":"2015","unstructured":"Tan AC, Goubier A, Kohrt HE. A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial. J Immunother Cancer. 2015;3:48.","journal-title":"J Immunother Cancer"},{"key":"1628_CR14","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1021\/acs.accounts.2c00360","volume":"55","author":"WH Li","year":"2022","unstructured":"Li WH, Su JY, Li YM. Rational design of T-Cell- and B-Cell-based therapeutic cancer vaccines. Acc Chem Res. 2022;55:2660\u201371.","journal-title":"Acc Chem Res"},{"key":"1628_CR15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12943-023-01776-0","volume":"22","author":"M Tagliamonte","year":"2023","unstructured":"Tagliamonte M, Cavalluzzo B, Mauriello A, Ragone C, Buonaguro FM, Tornesello ML, Buonaguro L. Molecular mimicry and cancer vaccine development. Mol Cancer. 2023;22:75.","journal-title":"Mol Cancer"},{"key":"1628_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121297","volume":"280","author":"DI Viswanath","year":"2022","unstructured":"Viswanath DI, Liu HC, Huston DP, Chua CYX, Grattoni A. Emerging biomaterial-based strategies for personalized therapeutic in situ cancer vaccines. Biomaterials. 2022;280: 121297.","journal-title":"Biomaterials"},{"key":"1628_CR17","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41563-020-0793-6","volume":"20","author":"S Liu","year":"2021","unstructured":"Liu S, Jiang Q, Zhao X, Zhao R, Wang Y, Wang Y, Liu J, Shang Y, Zhao S, Wu T, Zhang Y, Nie G, Ding B. A DNA nanodevice-based vaccine for cancer immunotherapy. Nat Mater. 2021;20:421\u201330.","journal-title":"Nat Mater"},{"key":"1628_CR18","doi-asserted-by":"publisher","first-page":"6258","DOI":"10.1039\/C4CS00511B","volume":"44","author":"Q He","year":"2015","unstructured":"He Q, Guo S, Qian Z, Chen X. Development of individualized anti-metastasis strategies by engineering nanomedicines. Chem Soc Rev. 2015;44:6258\u201386.","journal-title":"Chem Soc Rev"},{"key":"1628_CR19","first-page":"1564","volume":"186","author":"S Gerstberger","year":"2023","unstructured":"Gerstberger S, Jiang Q, Ganesh K. Metastasis Cell. 2023;186:1564\u201379.","journal-title":"Metastasis Cell"},{"key":"1628_CR20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.semcancer.2019.08.012","volume":"60","author":"Y Liang","year":"2020","unstructured":"Liang Y, Zhang H, Song X, Yang Q. Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets. Semin Cancer Biol. 2020;60:14\u201327.","journal-title":"Semin Cancer Biol"},{"key":"1628_CR21","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.semcancer.2022.02.003","volume":"86","author":"G Sharma","year":"2022","unstructured":"Sharma G, Pothuraju R, Kanchan RK, Batra SK, Siddiqui JA. Chemokines network in bone metastasis: vital regulators of seeding and soiling. Semin Cancer Biol. 2022;86:457\u201372.","journal-title":"Semin Cancer Biol"},{"key":"1628_CR22","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13045-022-01278-4","volume":"15","author":"H Xu","year":"2022","unstructured":"Xu H, Jiao D, Liu A, Wu K. Tumor organoids: applications in cancer modeling and potentials in precision medicine. J Hematol Oncol. 2022;15:58.","journal-title":"J Hematol Oncol"},{"key":"1628_CR23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20:101\u201324.","journal-title":"Nat Rev Drug Discov"},{"key":"1628_CR24","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1016\/j.jacc.2021.04.009","volume":"77","author":"VU Rao","year":"2021","unstructured":"Rao VU, Reeves DJ, Chugh AR, O\u2019Quinn R, Fradley MG, Raghavendra M, Dent S, Barac A, Lenihan D. Clinical approach to cardiovascular toxicity of oral antineoplastic agents: JACC state-of-the-art review. J Am Coll Cardiol. 2021;77:2693\u2013716.","journal-title":"J Am Coll Cardiol"},{"key":"1628_CR25","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.trecan.2020.05.001","volume":"6","author":"F Yang","year":"2020","unstructured":"Yang F, Zhao Z, Sun B, Chen Q, Sun J, He Z, Luo C. Nanotherapeutics for antimetastatic treatment. Trends Cancer. 2020;6:645\u201359.","journal-title":"Trends Cancer"},{"key":"1628_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201901255","volume":"32","author":"J Zhou","year":"2020","unstructured":"Zhou J, Kroll AV, Holay M, Fang RH, Zhang L. Biomimetic nanotechnology toward personalized vaccines. Adv Mater. 2020;32: e1901255.","journal-title":"Adv Mater"},{"key":"1628_CR27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jconrel.2018.07.011","volume":"285","author":"CK Chung","year":"2018","unstructured":"Chung CK, Da Silva CG, Kralisch D, Chan A, Ossendorp F, Cruz LJ. Combinatory therapy adopting nanoparticle-based cancer vaccination with immune checkpoint blockade for treatment of post-surgical tumor recurrences. J Contr Release: Off J Controlled Release Soc. 2018;285:56\u201366.","journal-title":"J Contr Release: Off J Controlled Release Soc"},{"key":"1628_CR28","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ajps.2019.10.006","volume":"15","author":"J Liu","year":"2020","unstructured":"Liu J, Miao L, Sui J, Hao Y, Huang G. Nanoparticle cancer vaccines: design considerations and recent advances. Asian J Pharm Sci. 2020;15:576\u201390.","journal-title":"Asian J Pharm Sci"},{"key":"1628_CR29","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s12951-022-01545-z","volume":"20","author":"Z Liao","year":"2022","unstructured":"Liao Z, Huang J, Lo PC, Lovell JF, Jin H, Yang K. Self-adjuvanting cancer nanovaccines. J Nanobiotechnol. 2022;20:345.","journal-title":"J Nanobiotechnol"},{"key":"1628_CR30","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12951-023-01977-1","volume":"21","author":"Y Li","year":"2023","unstructured":"Li Y, Li S, Jiang Z, Tan K, Meng Y, Zhang D, Ma X. Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions. J Nanobiotechnol. 2023;21:212.","journal-title":"J Nanobiotechnol"},{"key":"1628_CR31","doi-asserted-by":"publisher","first-page":"5185","DOI":"10.1021\/acs.nanolett.9b01571","volume":"19","author":"HY Kim","year":"2019","unstructured":"Kim HY, Kang M, Choo YW, Go SH, Kwon SP, Song SY, Sohn HS, Hong J, Kim BS. Immunomodulatory lipocomplex functionalized with photosensitizer-embedded cancer cell membrane inhibits tumor growth and metastasis. Nano Lett. 2019;19:5185\u201393.","journal-title":"Nano Lett"},{"key":"1628_CR32","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1038\/s41467-021-22308-8","volume":"12","author":"K Cheng","year":"2021","unstructured":"Cheng K, Zhao R, Li Y, Qi Y, Wang Y, Zhang Y, Qin H, Qin Y, Chen L, Li C, Liang J, Li Y, Xu J, Han X, Anderson GJ, Shi J, Ren L, Zhao X, Nie G. Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via plug-and-display technology. Nat Commun. 2021;12:2041.","journal-title":"Nat Commun"},{"key":"1628_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2019.119649","volume":"230","author":"X Liu","year":"2020","unstructured":"Liu X, Feng Z, Wang C, Su Q, Song H, Zhang C, Huang P, Liang XJ, Dong A, Kong D, Wang W. Co-localized delivery of nanomedicine and nanovaccine augments the postoperative cancer immunotherapy by amplifying T-cell responses. Biomaterials. 2020;230: 119649.","journal-title":"Biomaterials"},{"key":"1628_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.120893","volume":"274","author":"B Xiao","year":"2021","unstructured":"Xiao B, Li D, Xu H, Zhou X, Xu X, Qian Y, Yu F, Hu H, Zhou Z, Liu X, Gao J, Slater NKH, Shen Y, Tang J. An MRI-trackable therapeutic nanovaccine preventing cancer liver metastasis. Biomaterials. 2021;274: 120893.","journal-title":"Biomaterials"},{"issue":"4","key":"1628_CR35","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3390\/pharmaceutics10040205","volume":"10","author":"IM Adjei","year":"2018","unstructured":"Adjei IM, Temples MN, Brown SB, Sharma B. Targeted nanomedicine to treat bone metastasis. Pharmaceutics. 2018;10(4):205. https:\/\/doi.org\/10.3390\/pharmaceutics10040205.","journal-title":"Pharmaceutics"},{"key":"1628_CR36","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jconrel.2022.09.015","volume":"351","author":"Q Wang","year":"2022","unstructured":"Wang Q, Wang Z, Sun X, Jiang Q, Sun B, He Z, Zhang S, Luo C, Sun J. Lymph node-targeting nanovaccines for cancer immunotherapy. J Control Release. 2022;351:102\u201322.","journal-title":"J Control Release"},{"key":"1628_CR37","doi-asserted-by":"publisher","first-page":"6918","DOI":"10.1021\/acsnano.5b01042","volume":"9","author":"Y Guo","year":"2015","unstructured":"Guo Y, Wang D, Song Q, Wu T, Zhuang X, Bao Y, Kong M, Qi Y, Tan S, Zhang Z. Erythrocyte membrane-enveloped polymeric nanoparticles as nanovaccine for induction of antitumor immunity against melanoma. ACS Nano. 2015;9:6918\u201333.","journal-title":"ACS Nano"},{"key":"1628_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.120709","volume":"270","author":"F Chen","year":"2021","unstructured":"Chen F, Wang Y, Gao J, Saeed M, Li T, Wang W, Yu H. Nanobiomaterial-based vaccination immunotherapy of cancer. Biomaterials. 2021;270: 120709.","journal-title":"Biomaterials"},{"key":"1628_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202209910","volume":"35","author":"F Chen","year":"2023","unstructured":"Chen F, Li T, Zhang H, Saeed M, Liu X, Huang L, Wang X, Gao J, Hou B, Lai Y, Ding C, Xu Z, Xie Z, Luo M, Yu H. Acid-ionizable iron nanoadjuvant augments STING activation for personalized vaccination immunotherapy of cancer. Adv Mater. 2023;35: e2209910.","journal-title":"Adv Mater"},{"key":"1628_CR40","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nrclinonc.2016.144","volume":"14","author":"M Mohme","year":"2017","unstructured":"Mohme M, Riethdorf S, Pantel K. Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape. Nat Rev Clin Oncol. 2017;14:155\u201367.","journal-title":"Nat Rev Clin Oncol"},{"issue":"63","key":"1628_CR41","doi-asserted-by":"publisher","first-page":"eabg3551","DOI":"10.1126\/sciimmunol.abg3551","volume":"6","author":"H du Bois","year":"2021","unstructured":"du Bois H, Heim TA, Lund AW. Tumor-draining lymph nodes: at the crossroads of metastasis and immunity. Sci Immunol. 2021;6(63):eabg3551. https:\/\/doi.org\/10.1126\/sciimmunol.abg3551.","journal-title":"Sci Immunol"},{"key":"1628_CR42","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.ccell.2023.02.018","volume":"41","author":"L Patras","year":"2023","unstructured":"Patras L, Shaashua L, Matei I, Lyden D. Immune determinants of the pre-metastatic niche. Cancer Cell. 2023;41:546\u201372.","journal-title":"Cancer Cell"},{"key":"1628_CR43","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1016\/j.apsb.2023.03.004","volume":"13","author":"L Zhu","year":"2023","unstructured":"Zhu L, Yu X, Cao T, Deng H, Tang X, Lin Q, Zhou Q. Immune cell membrane-based biomimetic nanomedicine for treating cancer metastasis. Acta Pharm Sin B. 2023;13:2464\u201382.","journal-title":"Acta Pharm Sin B"},{"key":"1628_CR44","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002525","author":"L Zhu","year":"2023","unstructured":"Zhu L, Juan W, Gao H, Wang T, Xiao G, Chenggong H, Lin Q, Zhou Q. Tumor immune microenvironment-modulated nanostrategy for the treatment of lung cancer metastasis. Chinese Med J. 2023. https:\/\/doi.org\/10.1097\/CM9.0000000000002525.","journal-title":"Chinese Med J"},{"key":"1628_CR45","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41392-024-01885-2","volume":"9","author":"X Shi","year":"2024","unstructured":"Shi X, Wang X, Yao W, Shi D, Shao X, Lu Z, Chai Y, Song J, Tang W, Wang X. Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives. Signal Transduct Target Ther. 2024;9:192.","journal-title":"Signal Transduct Target Ther"},{"key":"1628_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.actbio.2021.02.030","volume":"125","author":"CS Yuan","year":"2021","unstructured":"Yuan CS, Deng ZW, Qin D, Mu YZ, Chen XG, Liu Y. Hypoxia-modulatory nanomaterials to relieve tumor hypoxic microenvironment and enhance immunotherapy: where do we stand? Acta Biomater. 2021;125:1\u201328.","journal-title":"Acta Biomater"},{"key":"1628_CR47","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jconrel.2018.02.026","volume":"275","author":"Q Zhou","year":"2018","unstructured":"Zhou Q, Li Y, Zhu Y, Yu C, Jia H, Bao B, Hu H, Xiao C, Zhang J, Zeng X, Wan Y, Xu H, Li Z, Yang X. Co-delivery nanoparticle to overcome metastasis promoted by insufficient chemotherapy. J Control Release. 2018;275:67\u201377.","journal-title":"J Control Release"},{"key":"1628_CR48","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.biomaterials.2018.10.019","volume":"188","author":"Y Li","year":"2019","unstructured":"Li Y, Xiao Y, Lin HP, Reichel D, Bae Y, Lee EY, Jiang Y, Huang X, Yang C, Wang Z. In vivo beta-catenin attenuation by the integrin alpha5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis. Biomaterials. 2019;188:160\u201372.","journal-title":"Biomaterials"},{"key":"1628_CR49","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12951-024-02354-2","volume":"22","author":"Q Du","year":"2024","unstructured":"Du Q, Luo Y, Xu L, Du C, Zhang W, Xu J, Liu Y, Liu B, Chen S, Wang Y, Wang Z, Ran H, Wang J, Guo D. Smart responsive Fe\/Mn nanovaccine triggers liver cancer immunotherapy via pyroptosis and pyroptosis-boosted cGAS-STING activation. J Nanobiotechnology. 2024;22:95.","journal-title":"J Nanobiotechnology"},{"key":"1628_CR50","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.7150\/thno.32462","volume":"9","author":"Y Huang","year":"2019","unstructured":"Huang Y, Zhou B, Luo H, Mao J, Huang Y, Zhang K, Mei C, Yan Y, Jin H, Gao J, Su Z, Pang P, Li D, Shan H. ZnAs@SiO(2) nanoparticles as a potential anti-tumor drug for targeting stemness and epithelial-mesenchymal transition in hepatocellular carcinoma via SHP-1\/JAK2\/STAT3 signaling. Theranostics. 2019;9:4391\u2013408.","journal-title":"Theranostics"},{"key":"1628_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202006000","volume":"17","author":"L Qin","year":"2021","unstructured":"Qin L, Zhang H, Zhou Y, Umeshappa CS, Gao H. Nanovaccine-based strategies to overcome challenges in the whole vaccination cascade for tumor immunotherapy. Small. 2021;17: e2006000.","journal-title":"Small"},{"issue":"43","key":"1628_CR52","doi-asserted-by":"publisher","first-page":"e2210452","DOI":"10.1002\/adma.202210452","volume":"36","author":"Y Bo","year":"2023","unstructured":"Bo Y, Wang H. Biomaterial\u2010based in situ cancer vaccines. Adv Mater. 2023;36(43):e2210452. https:\/\/doi.org\/10.1002\/adma.202210452.","journal-title":"Adv Mater"},{"key":"1628_CR53","doi-asserted-by":"publisher","first-page":"5408","DOI":"10.1038\/s41467-019-13368-y","volume":"10","author":"CR Perez","year":"2019","unstructured":"Perez CR, De Palma M. Engineering dendritic cell vaccines to improve cancer immunotherapy. Nat Commun. 2019;10:5408.","journal-title":"Nat Commun"},{"key":"1628_CR54","doi-asserted-by":"publisher","first-page":"6936","DOI":"10.7150\/thno.58173","volume":"11","author":"X Liang","year":"2021","unstructured":"Liang X, Li L, Li X, He T, Gong S, Zhu S, Zhang M, Wu Q, Gong C. A spontaneous multifunctional hydrogel vaccine amplifies the innate immune response to launch a powerful antitumor adaptive immune response. Theranostics. 2021;11:6936\u201349.","journal-title":"Theranostics"},{"key":"1628_CR55","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","volume":"20","author":"SK Wculek","year":"2020","unstructured":"Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20:7\u201324.","journal-title":"Nat Rev Immunol"},{"key":"1628_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/smtd.202201595","volume":"7","author":"X Zhao","year":"2023","unstructured":"Zhao X, Zhang J, Chen B, Ding X, Zhao N, Xu FJ. Rough nanovaccines boost antitumor immunity through the enhancement of vaccination cascade and immunogenic cell death induction. Small methods. 2023;7: e2201595.","journal-title":"Small methods"},{"key":"1628_CR57","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.1021\/acs.nanolett.9b00030","volume":"19","author":"L Zhang","year":"2019","unstructured":"Zhang L, Wu S, Qin Y, Fan F, Zhang Z, Huang C, Ji W, Lu L, Wang C, Sun H, Leng X, Kong D, Zhu D. Targeted codelivery of an antigen and dual agonists by hybrid nanoparticles for enhanced cancer immunotherapy. Nano Lett. 2019;19:4237\u201349.","journal-title":"Nano Lett"},{"issue":"20","key":"1628_CR58","doi-asserted-by":"publisher","first-page":"2300418","DOI":"10.1002\/advs.202300418","volume":"10","author":"C Xie","year":"2023","unstructured":"Xie C, You X, Zhang H, Li J, Wang L, Liu Y, Wang Z, Yao R, Tong T, Li M, Wang X. A nanovaccine based on adjuvant peptide FK-13 and l-phenylalanine poly (ester amide) enhances CD8+ T cell-mediated antitumor immunity. Adv Sci. 2023;10(20):2300418.","journal-title":"Adv Sci"},{"issue":"19","key":"1628_CR59","doi-asserted-by":"publisher","first-page":"e2301107","DOI":"10.1002\/advs.202301107","volume":"10","author":"W Sun","year":"2023","unstructured":"Sun W, Ji P, Zhou T, Li Z, Xing C, Zhang L, Wei M, Yang G, Yuan L. Ultrasound responsive nanovaccine armed with engineered cancer cell membrane and RNA to prevent foreseeable metastasis. Adv Sci. 2023;10(19):e2301107. https:\/\/doi.org\/10.1002\/advs.202301107.","journal-title":"Adv Sci"},{"key":"1628_CR60","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1021\/acs.nanolett.0c05039","volume":"21","author":"Y Yin","year":"2021","unstructured":"Yin Y, Li X, Ma H, Zhang J, Yu D, Zhao R, Yu S, Nie G, Wang H. In Situ transforming RNA nanovaccines from polyethylenimine functionalized graphene oxide hydrogel for durable cancer immunotherapy. Nano Lett. 2021;21:2224\u201331.","journal-title":"Nano Lett"},{"key":"1628_CR61","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018;17:261\u201379.","journal-title":"Nat Rev Drug Discov"},{"key":"1628_CR62","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","volume":"23","author":"CL Lorentzen","year":"2022","unstructured":"Lorentzen CL, Haanen JB, Met \u00d6, Svane IM. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. Lancet Oncol. 2022;23:e450\u20138.","journal-title":"Lancet Oncol"},{"key":"1628_CR63","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","volume":"20","author":"L Miao","year":"2021","unstructured":"Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy. Mol Cancer. 2021;20:41.","journal-title":"Mol Cancer"},{"key":"1628_CR64","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1384","volume":"13","author":"Y Li","year":"2023","unstructured":"Li Y, Wang M, Peng X, Yang Y, Chen Q, Liu J, She Q, Tan J, Lou C, Liao Z, Li X. mRNA vaccine in cancer therapy: current advance and future outlook. Clin Transl Med. 2023;13: e1384.","journal-title":"Clin Transl Med"},{"key":"1628_CR65","doi-asserted-by":"publisher","first-page":"6432","DOI":"10.1039\/D2NR07071E","volume":"15","author":"L Meng","year":"2023","unstructured":"Meng L, Teng Z, Yang S, Wang N, Guan Y, Chen X, Liu Y. Biomimetic nanoparticles for DC vaccination: a versatile approach to boost cancer immunotherapy. Nanoscale. 2023;15:6432\u201355.","journal-title":"Nanoscale"},{"key":"1628_CR66","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/s41565-020-00781-4","volume":"15","author":"J Xu","year":"2020","unstructured":"Xu J, Lv J, Zhuang Q, Yang Z, Cao Z, Xu L, Pei P, Wang C, Wu H, Dong Z, Chao Y, Wang C, Yang K, Peng R, Cheng Y, Liu Z. A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy. Nat Nanotechnol. 2020;15:1043\u201352.","journal-title":"Nat Nanotechnol"},{"key":"1628_CR67","doi-asserted-by":"publisher","first-page":"14475","DOI":"10.1021\/acsnano.3c00901","volume":"17","author":"W Shi","year":"2023","unstructured":"Shi W, Feng W, Li S, Cui Y, Liu S, Jiang H, Liu Y, Zhang H. Ferroptosis and necroptosis produced autologous tumor cell lysates co-delivering with combined immnoadjuvants as personalized in situ nanovaccines for antitumor immunity. ACS Nano. 2023;17:14475\u201393.","journal-title":"ACS Nano"},{"key":"1628_CR68","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.ccell.2024.05.005","volume":"42","author":"P Guasp","year":"2024","unstructured":"Guasp P, Reiche C, Sethna Z, Balachandran VP. RNA vaccines for cancer: principles to practice. Cancer Cell. 2024;42:1163\u201384.","journal-title":"Cancer Cell"},{"key":"1628_CR69","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202401631","volume":"20","author":"N Desai","year":"2024","unstructured":"Desai N, Chavda V, Singh TRR, Thorat ND, Vora LK. Cancer nanovaccines: nanomaterials and clinical perspectives. Small. 2024;20: e2401631.","journal-title":"Small"},{"key":"1628_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109236","volume":"112","author":"Y Song","year":"2022","unstructured":"Song Y, Zhang Y. Research progress of neoantigens in gynecologic cancers. Int Immunopharmacol. 2022;112: 109236.","journal-title":"Int Immunopharmacol"},{"key":"1628_CR71","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1021\/acschembio.5b00239","volume":"10","author":"NR Bennett","year":"2015","unstructured":"Bennett NR, Zwick DB, Courtney AH, Kiessling LL. Multivalent antigens for promoting B and T cell activation. ACS Chem Biol. 2015;10:1817\u201324.","journal-title":"ACS Chem Biol"},{"key":"1628_CR72","doi-asserted-by":"publisher","first-page":"763086","DOI":"10.3389\/fimmu.2021.763086","volume":"12","author":"C Wang","year":"2021","unstructured":"Wang C, Zainal NS, Chai SJ, Dickie J, Gan CP, Zulaziz N, Lye BKW, Sutavani RV, Ottensmeier CH, King EV, Abraham MT, Ismail SMB, Lau SH, Kallarakkal TG, Mun KS, Zain RB, Abdul Rahman ZA, Thomas GJ, Cheong SC, Savelyeva N, Lim KP. DNA vaccines targeting novel cancer-associated antigens frequently expressed in head and neck cancer enhance the efficacy of checkpoint inhibitor. Front Immunol. 2021;12:763086. https:\/\/doi.org\/10.3389\/fimmu.2021.763086.","journal-title":"Front Immunol"},{"key":"1628_CR73","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","volume":"18","author":"E Blass","year":"2021","unstructured":"Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021;18:215\u201329.","journal-title":"Nat Rev Clin Oncol"},{"key":"1628_CR74","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/14712598.2024.2341744","volume":"24","author":"W Jia","year":"2024","unstructured":"Jia W, Shen X, Guo Z, Cheng X, Zhao R. The future of cancer vaccines against colorectal cancer. Expert Opin Biol Ther. 2024;24:269\u201384.","journal-title":"Expert Opin Biol Ther"},{"key":"1628_CR75","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41577-020-0390-6","volume":"21","author":"D Dersh","year":"2021","unstructured":"Dersh D, Holly J, Yewdell JW. A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion. Nat Rev Immunol. 2021;21:116\u201328.","journal-title":"Nat Rev Immunol"},{"key":"1628_CR76","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.biomaterials.2018.05.015","volume":"174","author":"LX Zhang","year":"2018","unstructured":"Zhang LX, Xie XX, Liu DQ, Xu ZP, Liu RT. Efficient co-delivery of neo-epitopes using dispersion-stable layered double hydroxide nanoparticles for enhanced melanoma immunotherapy. Biomaterials. 2018;174:54\u201366.","journal-title":"Biomaterials"},{"key":"1628_CR77","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40425-017-0270-1","volume":"5","author":"B Donaldson","year":"2017","unstructured":"Donaldson B, Al-Barwani F, Pelham SJ, Young K, Ward VK, Young SL. Multi-target chimaeric VLP as a therapeutic vaccine in a model of colorectal cancer. J Immunother Cancer. 2017;5:69.","journal-title":"J Immunother Cancer"},{"key":"1628_CR78","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, Ceglia N, Guasp P, Chu A, Yu R, Chandra AK, Waters T, Ruan J, Amisaki M, Zebboudj A, Odgerel Z, Payne G, Derhovanessian E, Muller F, Rhee I, Yadav M, Dobrin A, Sadelain M, Luksza M, Cohen N, Tang L, Basturk O, Gonen M, Katz S, Do RK, Epstein AS, Momtaz P, Park W, Sugarman R, Varghese AM, Won E, Desai A, Wei AC, D\u2019Angelica MI, Kingham TP, Mellman I, Merghoub T, Wolchok JD, Sahin U, Tureci O, Greenbaum BD, Jarnagin WR, Drebin J, O\u2019Reilly EM, Balachandran VP. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618:144\u201350.","journal-title":"Nature"},{"key":"1628_CR79","doi-asserted-by":"publisher","first-page":"15226","DOI":"10.1021\/acsnano.2c06560","volume":"16","author":"L Jin","year":"2022","unstructured":"Jin L, Yang D, Song Y, Li D, Xu W, Zhu Y, Xu CF, Lu Y, Yang X. In Situ programming of nanovaccines for lymph node-targeted delivery and cancer immunotherapy. ACS Nano. 2022;16:15226\u201336.","journal-title":"ACS Nano"},{"key":"1628_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121794","volume":"289","author":"S Zhang","year":"2022","unstructured":"Zhang S, Feng Y, Meng M, Li Z, Li H, Lin L, Xu C, Chen J, Hao K, Tang Z, Tian H, Chen X. A generally minimalist strategy of constructing biomineralized high-efficiency personalized nanovaccine combined with immune checkpoint blockade for cancer immunotherapy. Biomaterials. 2022;289: 121794.","journal-title":"Biomaterials"},{"issue":"38","key":"1628_CR81","doi-asserted-by":"publisher","first-page":"16381","DOI":"10.1002\/anie.202005111","volume":"59","author":"B Ding","year":"2020","unstructured":"Ding B, Zheng P, Jiang F, Zhao Y, Wang M, Chang M, Ma PA, Lin J. MnOx nanospikes as nanoadjuvants and immunogenic cell death drugs with enhanced antitumor immunity and antimetastatic effect. Angew Chem Int Ed. 2020;59(38):16381\u20134.","journal-title":"Angew Chem Int Ed"},{"key":"1628_CR82","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.jconrel.2023.02.015","volume":"355","author":"Y Yi","year":"2023","unstructured":"Yi Y, Yu M, Li W, Zhu D, Mei L, Ou M. Vaccine-like nanomedicine for cancer immunotherapy. J Control Release. 2023;355:760\u201378.","journal-title":"J Control Release"},{"key":"1628_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2020.119795","volume":"235","author":"S Zhou","year":"2020","unstructured":"Zhou S, Huang Y, Chen Y, Liu S, Xu M, Jiang T, Song Q, Jiang G, Gu X, Gao X, Chen J. Engineering ApoE3-incorporated biomimetic nanoparticle for efficient vaccine delivery to dendritic cells via macropinocytosis to enhance cancer immunotherapy. Biomaterials. 2020;235: 119795.","journal-title":"Biomaterials"},{"key":"1628_CR84","doi-asserted-by":"publisher","first-page":"5401","DOI":"10.1021\/acs.nanolett.8b01592","volume":"18","author":"MI Lerner","year":"2018","unstructured":"Lerner MI, Mikhaylov G, Tsukanov AA, Lozhkomoev AS, Gutmanas E, Gotman I, Bratovs A, Turk V, Turk B, Psakhye SG, Vasiljeva O. Crumpled aluminum hydroxide nanostructures as a microenvironment dysregulation agent for cancer treatment. Nano Lett. 2018;18:5401\u201310.","journal-title":"Nano Lett"},{"key":"1628_CR85","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202007293","volume":"33","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Ma S, Liu X, Xu Y, Zhao J, Si X, Li H, Huang Z, Wang Z, Tang Z, Song W, Chen X. Supramolecular assembled programmable nanomedicine as in situ cancer vaccine for cancer immunotherapy. Adv Mater. 2021;33: e2007293.","journal-title":"Adv Mater"},{"key":"1628_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2021.101007","volume":"83","author":"J Zhou","year":"2022","unstructured":"Zhou J, Ventura CJ, Fang RH, Zhang L. Nanodelivery of STING agonists against cancer and infectious diseases. Mol Aspects Med. 2022;83: 101007.","journal-title":"Mol Aspects Med"},{"key":"1628_CR87","first-page":"1","volume":"20","author":"A Habib","year":"2023","unstructured":"Habib A, Anjum KM, Iqbal R, Jaffar G, Ashraf Z, Khalid MS, Taj MU, Zainab SW, Umair M, Zohaib M, Khalid T. Vaccine adjuvants: selection criteria, mechanism of action associated with immune responses and future directions. Iran J Immunol. 2023;20:1\u201315.","journal-title":"Iran J Immunol"},{"key":"1628_CR88","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1039\/D2CS00647B","volume":"52","author":"X Zhang","year":"2023","unstructured":"Zhang X, Yang B, Ni Q, Chen X. Materials engineering strategies for cancer vaccine adjuvant development. Chem Soc Rev. 2023;52:2886\u2013910.","journal-title":"Chem Soc Rev"},{"key":"1628_CR89","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","volume":"8","author":"T Zhao","year":"2023","unstructured":"Zhao T, Cai Y, Jiang Y, He X, Wei Y, Yu Y, Tian X. Vaccine adjuvants: mechanisms and platforms. Signal Transduct Target Ther. 2023;8:283.","journal-title":"Signal Transduct Target Ther"},{"key":"1628_CR90","doi-asserted-by":"publisher","first-page":"e2203100","DOI":"10.1002\/smll.202203100","volume":"18","author":"X Li","year":"2022","unstructured":"Li X, Zhang Y, Wu X, Chen J, Yang M, Ma F, Shi L. In situ antigen-capturing nanochaperone toward personalized nanovaccine for cancer immunotherapy. Small. 2022;18:e2203100.","journal-title":"Small"},{"key":"1628_CR91","first-page":"107","volume":"16","author":"X Xie","year":"2022","unstructured":"Xie X, Feng Y, Zhang H, Su Q, Song T, Yang G, Li N, Wei X, Li T, Qin X, Li S, Wu C, Zhang X, Wang G, Liu Y, Yang H. Remodeling tumor immunosuppressive microenvironment via a novel bioactive nanovaccines potentiates the efficacy of cancer immunotherapy. Bioact Mater. 2022;16:107\u201319.","journal-title":"Bioact Mater"},{"key":"1628_CR92","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201801320","volume":"8","author":"ES Lee","year":"2019","unstructured":"Lee ES, Shin JM, Son S, Ko H, Um W, Song SH, Lee JA, Park JH. Recent advances in polymeric nanomedicines for cancer immunotherapy. Adv Healthcare Mater. 2019;8: e1801320.","journal-title":"Adv Healthcare Mater"},{"issue":"35","key":"1628_CR93","doi-asserted-by":"publisher","first-page":"6326","DOI":"10.1126\/sciadv.abi6326","volume":"7","author":"Y Zhai","year":"2021","unstructured":"Zhai Y, He X, Li Y, Han R, Ma Y, Gao P, Qian Z, Gu Y, Li S. A splenic-targeted versatile antigen courier: iPSC wrapped in coalescent erythrocyte-liposome as tumor nanovaccine. Sci Adv. 2021;7(35):6326.","journal-title":"Sci Adv"},{"issue":"14","key":"1628_CR94","doi-asserted-by":"publisher","first-page":"11869","DOI":"10.3390\/ijms241411869","volume":"24","author":"L Kaps","year":"2023","unstructured":"Kaps L, Limeres MJ, Schneider P, Svensson M, Zeyn Y, Fraude S, Cacicedo ML, Galle PR, Gehring S, Bros M. Liver cell type-specific targeting by nanoformulations for therapeutic applications. Int J Mol Sci. 2023;24(14):11869.","journal-title":"Int J Mol Sci"},{"issue":"41","key":"1628_CR95","doi-asserted-by":"publisher","first-page":"2301686","DOI":"10.1002\/adma.202301686","volume":"35","author":"W Gu","year":"2023","unstructured":"Gu W, An J, Li Y, Yang Y, Wang S, Shan H, Li S, Li H, Liu G, Li K, Yin Y. Tuning the organ tropism of polymersome for spleen-selective nanovaccine delivery to boost cancer immunotherapy. Adv Mater. 2023;35(41):2301686.","journal-title":"Adv Mater"},{"issue":"22","key":"1628_CR96","doi-asserted-by":"publisher","first-page":"4369","DOI":"10.3390\/polym15224369","volume":"15","author":"M P\u00e9rez-Ferreiro","year":"2023","unstructured":"P\u00e9rez-Ferreiro M, Abelairas MA, Criado A, G\u00f3mez IJ, Mosquera J. Dendrimers: exploring their wide structural variety and applications. Polymers. 2023;15(22):4369.","journal-title":"Polymers"},{"issue":"24","key":"1628_CR97","doi-asserted-by":"publisher","first-page":"4494","DOI":"10.3390\/nano12244494","volume":"12","author":"O Afzal","year":"2022","unstructured":"Afzal O, Altamimi AS, Nadeem MS, Alzarea SI, Almalki WH, Tariq A, Mubeen B, Murtaza BN, Iftikhar S, Riaz N, Kazmi I. Nanoparticles in drug delivery: from history to therapeutic applications. Nanomaterials. 2022;12(24):4494.","journal-title":"Nanomaterials"},{"issue":"1","key":"1628_CR98","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3390\/pharmaceutics15010148","volume":"15","author":"N Knauer","year":"2022","unstructured":"Knauer N, Pashkina E, Aktanova A, Boeva O, Arkhipova V, Barkovskaya M, Meschaninova M, Karpus A, Majoral JP, Kozlov V, Apartsin E. Effects of cationic dendrimers and their complexes with microRNAs on immunocompetent cells. Pharmaceutics. 2022;15(1):148.","journal-title":"Pharmaceutics"},{"key":"1628_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121303","volume":"280","author":"S Chowdhury","year":"2022","unstructured":"Chowdhury S, Toth I, Stephenson RJ. Dendrimers in vaccine delivery: recent progress and advances. Biomaterials. 2022;280: 121303.","journal-title":"Biomaterials"},{"key":"1628_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biomaterials.2019.03.037","volume":"207","author":"J Xu","year":"2019","unstructured":"Xu J, Wang H, Xu L, Chao Y, Wang C, Han X, Dong Z, Chang H, Peng R, Cheng Y, Liu Z. Nanovaccine based on a protein-delivering dendrimer for effective antigen cross-presentation and cancer immunotherapy. Biomaterials. 2019;207:1\u20139.","journal-title":"Biomaterials"},{"issue":"1013\u20131026","key":"1628_CR101","first-page":"e1014","volume":"26","author":"W Tong","year":"2019","unstructured":"Tong W, Maira M, Roychoudhury R, Galan A, Brahimi F, Gilbert M, Cunningham AM, Josephy S, Pirvulescu I, Moffett S, Saragovi HU. Vaccination with tumor-ganglioside glycomimetics activates a selective immunity that affords cancer therapy. Cell Chem Biol. 2019;26(1013\u20131026):e1014.","journal-title":"Cell Chem Biol"},{"key":"1628_CR102","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202305215","volume":"35","author":"P Zhang","year":"2023","unstructured":"Zhang P, Li Z, Cao W, Tang J, Xia Y, Peng L, Ma J. A PD-L1 antibody-conjugated PAMAM dendrimer nanosystem for simultaneously inhibiting glycolysis and promoting immune response in fighting breast cancer. Adv Mater. 2023;35: e2305215.","journal-title":"Adv Mater"},{"issue":"11","key":"1628_CR103","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.3390\/pharmaceutics15112622","volume":"15","author":"L Cheng","year":"2023","unstructured":"Cheng L, Yu J, Hao T, Wang W, Wei M, Li G. Advances in polymeric micelles: responsive and targeting approaches for cancer immunotherapy in the tumor microenvironment. Pharmaceutics. 2023;15(11):2622.","journal-title":"Pharmaceutics"},{"key":"1628_CR104","doi-asserted-by":"publisher","first-page":"13014","DOI":"10.1039\/D3SC03543C","volume":"14","author":"L Ghani","year":"2023","unstructured":"Ghani L, Kim S, Ehsan M, Lan B, Poulsen IH, Dev C, Katsube S, Byrne B, Guan L, Loland CJ, Liu X, Im W, Chae PS. Melamine-cored glucosides for membrane protein solubilization and stabilization: importance of water-mediated intermolecular hydrogen bonding in detergent performance. Chem Sci. 2023;14:13014\u201324.","journal-title":"Chem Sci"},{"key":"1628_CR105","doi-asserted-by":"publisher","first-page":"6639","DOI":"10.2147\/IJN.S431409","volume":"18","author":"J Yang","year":"2023","unstructured":"Yang J, Shang J, Yang L, Wei D, Wang X, Deng Q, Zhong Z, Ye Y, Zhou M. Nanotechnology-based drug delivery systems for Honokiol: enhancing therapeutic potential and overcoming limitations. Int J Nanomedicine. 2023;18:6639\u201365.","journal-title":"Int J Nanomedicine"},{"key":"1628_CR106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2021.04.006","volume":"334","author":"M Elsabahy","year":"2021","unstructured":"Elsabahy M, Song Y, Eissa NG, Khan S, Hamad MA, Wooley KL. Morphologic design of sugar-based polymer nanoparticles for delivery of antidiabetic peptides. J Control Release. 2021;334:1\u201310.","journal-title":"J Control Release"},{"key":"1628_CR107","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jconrel.2021.04.014","volume":"334","author":"J Kaur","year":"2021","unstructured":"Kaur J, Mishra V, Singh SK, Gulati M, Kapoor B, Chellappan DK, Gupta G, Dureja H, Anand K, Dua K, Khatik GL, Gowthamarajan K. Harnessing amphiphilic polymeric micelles for diagnostic and therapeutic applications: Breakthroughs and bottlenecks. J Control Release. 2021;334:64\u201395.","journal-title":"J Control Release"},{"key":"1628_CR108","doi-asserted-by":"publisher","first-page":"12127","DOI":"10.1021\/acsnano.2c12356","volume":"17","author":"Y Li","year":"2023","unstructured":"Li Y, Wang J, Li Y, Luo J, Liu F, Chen T, Ji Y, Yang H, Wang Z, Zhao Y. Attenuating uncontrolled inflammation by radical trapping chiral polymer micelles. ACS Nano. 2023;17:12127\u201339.","journal-title":"ACS Nano"},{"key":"1628_CR109","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jconrel.2021.08.061","volume":"338","author":"J Ren","year":"2021","unstructured":"Ren J, Cao Y, Li L, Wang X, Lu H, Yang J, Wang S. Self-assembled polymeric micelle as a novel mRNA delivery carrier. J Control Release. 2021;338:537\u201347.","journal-title":"J Control Release"},{"key":"1628_CR110","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1021\/acsami.1c18117","volume":"14","author":"H Ren","year":"2022","unstructured":"Ren H, Li J, Liu G, Sun Y, Yang X, Jiang Z, Zhang J, Lovell JF, Zhang Y. Anticancer vaccination with immunogenic micelles that capture and release pristine CD8(+) T-cell epitopes and adjuvants. ACS Appl Mater Interfaces. 2022;14:2510\u201321.","journal-title":"ACS Appl Mater Interfaces"},{"key":"1628_CR111","doi-asserted-by":"publisher","first-page":"115136","DOI":"10.1016\/j.addr.2023.115136","volume":"203","author":"A Yaghmur","year":"2023","unstructured":"Yaghmur A, \u00d8stergaard J, Mu H. Lipid nanoparticles for targeted delivery of anticancer therapeutics: recent advances in development of siRNA and lipoprotein-mimicking nanocarriers. Adv Drug Deliv Rev. 2023;203:115136.","journal-title":"Adv Drug Deliv Rev"},{"key":"1628_CR112","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1093\/annonc\/mdh393","volume":"15","author":"S Chan","year":"2004","unstructured":"Chan S, Davidson N, Juozaityte E, Erdkamp F, Pluzanska A, Azarnia N, Lee LW. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann Oncol. 2004;15:1527\u201334.","journal-title":"Ann Oncol"},{"key":"1628_CR113","first-page":"7510","volume":"38","author":"JE Lancet","year":"2020","unstructured":"Lancet JE, Uy GL, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Bixby D, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Faderl S, Chang Y-L, Cortes J. Five-year final results of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk\/secondary. AML. 2020;38:7510\u20137510.","journal-title":"AML."},{"key":"1628_CR114","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41392-022-00996-y","volume":"7","author":"M Li","year":"2022","unstructured":"Li M, Wang H, Tian L, Pang Z, Yang Q, Huang T, Fan J, Song L, Tong Y, Fan H. COVID-19 vaccine development: milestones, lessons and prospects. Signal Transduct Target Ther. 2022;7:146.","journal-title":"Signal Transduct Target Ther"},{"key":"1628_CR115","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S1470-2045(18)30254-7","volume":"19","author":"B Dreno","year":"2018","unstructured":"Dreno B, Thompson JF, Smithers BM, Santinami M, Jouary T, Gutzmer R, Levchenko E, Rutkowski P, Grob JJ, Korovin S, Drucis K, Grange F, Machet L, Hersey P, Krajsova I, Testori A, Conry R, Guillot B, Kruit WHJ, Kirkwood JM. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19:916\u201329.","journal-title":"Lancet Oncol"},{"issue":"12","key":"1628_CR116","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.3390\/pharmaceutics15122774","volume":"15","author":"A Arabi","year":"2023","unstructured":"Arabi A, Aria S, Maniaci B, Mann K, Martinson H, Kullberg M. Enhancing T Cell and antibody response in Mucin-1 transgenic mice through co-delivery of tumor-associated Mucin-1 antigen and TLR agonists in C3-liposomes. Pharmaceutics. 2023;15(12):2774.","journal-title":"Pharmaceutics"},{"key":"1628_CR117","doi-asserted-by":"publisher","first-page":"10859","DOI":"10.1039\/D3TB01317K","volume":"11","author":"KS Pradyuth","year":"2023","unstructured":"Pradyuth KS, Salunkhe SA, Singh AK, Chitkara D, Mittal A. Belinostat loaded lipid-polymer hybrid nanoparticulate delivery system for breast cancer: improved pharmacokinetics and biodistribution in a tumor model. J Mater Chem B. 2023;11:10859\u201372.","journal-title":"J Mater Chem B"},{"key":"1628_CR118","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jconrel.2022.11.042","volume":"353","author":"V Andretto","year":"2023","unstructured":"Andretto V, Repellin M, Pujol M, Almouazen E, Sidi-Boumedine J, Granjon T, Zhang H, Remaut K, Jordheim LP, Briancon S, Keil IS, Vascotto F, Walzer KC, Sahin U, Haas H, Kryza D, Lollo G. Hybrid core-shell particles for mRNA systemic delivery. J Control Release. 2023;353:1037\u201349.","journal-title":"J Control Release"},{"key":"1628_CR119","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.jconrel.2022.11.009","volume":"352","author":"N Rajana","year":"2022","unstructured":"Rajana N, Mounika A, Chary PS, Bhavana V, Urati A, Khatri D, Singh SB, Mehra NK. Multifunctional hybrid nanoparticles in diagnosis and therapy of breast cancer. J Control Release. 2022;352:1024\u201347.","journal-title":"J Control Release"},{"key":"1628_CR120","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12943-023-01849-0","volume":"22","author":"KR Gajbhiye","year":"2023","unstructured":"Gajbhiye KR, Salve R, Narwade M, Sheikh A, Kesharwani P, Gajbhiye V. Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics. Mol Cancer. 2023;22:160.","journal-title":"Mol Cancer"},{"key":"1628_CR121","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ijpharm.2018.10.054","volume":"553","author":"C Liu","year":"2018","unstructured":"Liu C, Chu X, Yan M, Qi J, Liu H, Gao F, Gao R, Ma G, Ma Y. Encapsulation of Poly I: C and the natural phosphodiester CpG ODN enhanced the efficacy of a hyaluronic acid-modified cationic lipid-PLGA hybrid nanoparticle vaccine in TC-1-grafted tumors. Int J Pharm. 2018;553:327\u201337.","journal-title":"Int J Pharm"},{"key":"1628_CR122","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.2147\/DDDT.S202818","volume":"13","author":"Y Shao","year":"2019","unstructured":"Shao Y, Luo W, Guo Q, Li X, Zhang Q, Li J. In vitro and in vivo effect of hyaluronic acid modified, doxorubicin and gallic acid co-delivered lipid-polymeric hybrid nano-system for leukemia therapy. Drug Des Devel Ther. 2019;13:2043\u201355.","journal-title":"Drug Des Devel Ther"},{"key":"1628_CR123","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.biomaterials.2019.03.012","volume":"206","author":"D Zhu","year":"2019","unstructured":"Zhu D, Hu C, Fan F, Qin Y, Huang C, Zhang Z, Lu L, Wang H, Sun H, Leng X, Wang C, Kong D, Zhang L. Co-delivery of antigen and dual agonists by programmed mannose-targeted cationic lipid-hybrid polymersomes for enhanced vaccination. Biomaterials. 2019;206:25\u201340.","journal-title":"Biomaterials"},{"key":"1628_CR124","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jconrel.2015.11.009","volume":"240","author":"KS Soni","year":"2016","unstructured":"Soni KS, Desale SS, Bronich TK. Nanogels: an overview of properties, biomedical applications and obstacles to clinical translation. J Control Release. 2016;240:109\u201326.","journal-title":"J Control Release"},{"key":"1628_CR125","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jconrel.2022.05.004","volume":"347","author":"D Muraoka","year":"2022","unstructured":"Muraoka D, Harada N, Shiku H, Akiyoshi K. Self-assembled polysaccharide nanogel delivery system for overcoming tumor immune resistance. J Control Release. 2022;347:175\u201382.","journal-title":"J Control Release"},{"issue":"22","key":"1628_CR126","doi-asserted-by":"publisher","first-page":"e2301789","DOI":"10.1002\/advs.202301789","volume":"10","author":"P Ji","year":"2023","unstructured":"Ji P, Sun W, Zhang S, Xing Y, Wang C, Wei M, Li Q, Ji G, Yang G. Modular hydrogel vaccine for programmable and coordinate elicitation of cancer immunotherapy. Adv Sci. 2023;10(22):e2301789. https:\/\/doi.org\/10.1002\/advs.202301789.","journal-title":"Adv Sci"},{"key":"1628_CR127","doi-asserted-by":"publisher","first-page":"9778","DOI":"10.1021\/acs.nanolett.3c02449","volume":"23","author":"Y Hu","year":"2023","unstructured":"Hu Y, Gao S, Lu H, Tan S, Chen F, Ke Y, Ying JY. A self-immolative DNA nanogel vaccine toward cancer immunotherapy. Nano Lett. 2023;23:9778\u201387.","journal-title":"Nano Lett"},{"key":"1628_CR128","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1007\/s00262-021-02892-w","volume":"70","author":"T Ishikawa","year":"2021","unstructured":"Ishikawa T, Kageyama S, Miyahara Y, Okayama T, Kokura S, Wang L, Sato E, Yagita H, Itoh Y, Shiku H. Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients. Cancer Immunol Immunother. 2021;70:3081\u201391.","journal-title":"Cancer Immunol Immunother"},{"key":"1628_CR129","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s40364-023-00534-0","volume":"11","author":"Z Pang","year":"2023","unstructured":"Pang Z, Lu MM, Zhang Y, Gao Y, Bai JJ, Gu JY, Xie L, Wu WZ. Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges. Biomark Res. 2023;11:104.","journal-title":"Biomark Res"},{"issue":"11","key":"1628_CR130","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.3390\/vaccines11111717","volume":"11","author":"C-R Shyr","year":"2023","unstructured":"Shyr C-R, Liu L-C, Chien H-S, Huang C-P. Immunotherapeutic agents for intratumoral immunotherapy. Vaccines. 2023;11(11):1717. https:\/\/doi.org\/10.3390\/vaccines11111717.","journal-title":"Vaccines"},{"issue":"11","key":"1628_CR131","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.3390\/vaccines11111633","volume":"11","author":"A Hargrave","year":"2023","unstructured":"Hargrave A, Mustafa AS, Hanif A, Tunio JH, Hanif SNM. Recent advances in cancer immunotherapy with a focus on FDA-approved vaccines and neoantigen-based vaccines. Vaccines. 2023;11(11):1633. https:\/\/doi.org\/10.3390\/vaccines11111633.","journal-title":"Vaccines"},{"key":"1628_CR132","doi-asserted-by":"publisher","first-page":"21455","DOI":"10.1021\/acsnano.3c06233","volume":"17","author":"R Huang","year":"2023","unstructured":"Huang R, Zhou P, Chen B, Zhu Y, Chen X, Min Y. Stimuli-responsive nanoadjuvant rejuvenates robust immune responses to sensitize cancer immunotherapy. ACS Nano. 2023;17:21455\u201369.","journal-title":"ACS Nano"},{"key":"1628_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.121091","volume":"608","author":"Z Liang","year":"2021","unstructured":"Liang Z, Cui X, Yang L, Hu Q, Li D, Zhang X, Han L, Shi S, Shen Y, Zhao W, Ju Q, Deng X, Wu Y, Sheng W. Co-assembled nanocomplexes of peptide neoantigen Adpgk and Toll-like receptor 9 agonist CpG ODN for efficient colorectal cancer immunotherapy. Int J Pharm. 2021;608: 121091.","journal-title":"Int J Pharm"},{"issue":"10","key":"1628_CR134","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.3390\/vaccines11101599","volume":"11","author":"L Ni","year":"2023","unstructured":"Ni L. Advances in mRNA-based cancer vaccines. Vaccines. 2023;11(10):1599. https:\/\/doi.org\/10.3390\/vaccines11101599.","journal-title":"Vaccines"},{"key":"1628_CR135","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/14760584.2022.2012456","volume":"21","author":"G Richard","year":"2022","unstructured":"Richard G, Princiotta MF, Bridon D, Martin WD, Steinberg GD, De Groot AS. Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy. Expert Rev Vaccines. 2022;21:173\u201384.","journal-title":"Expert Rev Vaccines"},{"key":"1628_CR136","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104198","volume":"193","author":"Z Duan","year":"2023","unstructured":"Duan Z, Yang D, Yuan P, Dai X, Chen G, Wu D. Advances, opportunities and challenges in developing therapeutic cancer vaccines. Crit Rev Oncol Hematol. 2023;193: 104198.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"1628_CR137","doi-asserted-by":"publisher","first-page":"e202315282","DOI":"10.1002\/anie.202315282","volume":"63","author":"F Wang","year":"2024","unstructured":"Wang F, Xie M, Huang Y, Liu Y, Liu X, Zhu L, Zhu X, Guo Y, Zhang C. In situ vaccination with an injectable nucleic acid hydrogel for synergistic cancer immunotherapy. Angew Chem Int Ed. 2024;63(4):e202315282.","journal-title":"Angew Chem Int Ed"},{"issue":"2","key":"1628_CR138","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3390\/vaccines11020394","volume":"11","author":"YJ Xie","year":"2023","unstructured":"Xie YJ, Liu WQ, Li D, Hou JC, Coghi PS, Fan XX. Overcoming suppressive tumor microenvironment by vaccines in solid tumor. Vaccines. 2023;11(2):394.","journal-title":"Vaccines"},{"key":"1628_CR139","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1080\/21645515.2021.1921524","volume":"17","author":"H Zhang","year":"2021","unstructured":"Zhang H, Xia X. RNA cancer vaccines: developing mRNA nanovaccine with self-adjuvant property for cancer immunotherapy. Hum Vaccin Immunother. 2021;17:2995\u20138.","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"1628_CR140","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3390\/nano10020364","volume":"10","author":"I G\u00f3mez-Aguado","year":"2020","unstructured":"G\u00f3mez-Aguado I, Rodr\u00edguez-Castej\u00f3n J, Vicente-Pascual M, Rodr\u00edguez-Gasc\u00f3n A, Solin\u00eds M\u00c1, del Pozo-Rodr\u00edguez A. Nanomedicines to deliver mRNA: state of the art and future perspectives. Nanomaterials. 2020;10(2):364.","journal-title":"Nanomaterials"},{"issue":"3","key":"1628_CR141","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3390\/vaccines9030244","volume":"9","author":"MM Rahman","year":"2021","unstructured":"Rahman MM, Zhou N, Huang J. An overview on the development of mRNA-based vaccines and their formulation strategies for improved antigen expression in vivo. Vaccines. 2021;9(3):244.","journal-title":"Vaccines"},{"key":"1628_CR142","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.jconrel.2022.01.047","volume":"343","author":"YJ Yoo","year":"2022","unstructured":"Yoo YJ, Lee CH, Park SH, Lim YT. Nanoparticle-based delivery strategies of multifaceted immunomodulatory RNA for cancer immunotherapy. J Control Release. 2022;343:564\u201383.","journal-title":"J Control Release"},{"key":"1628_CR143","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.jconrel.2023.08.022","volume":"361","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Liu F, Tan L, Li X, Dai Z, Cheng Q, Liu J, Wang Y, Huang L, Wang L, Wang Z. LncRNA-edited biomimetic nanovaccines combined with anti-TIM-3 for augmented immune checkpoint blockade immunotherapy. J Control Release. 2023;361:671\u201380.","journal-title":"J Control Release"},{"key":"1628_CR144","doi-asserted-by":"publisher","first-page":"11623","DOI":"10.1021\/acsnano.0c04188","volume":"14","author":"TL Nguyen","year":"2020","unstructured":"Nguyen TL, Yin Y, Choi Y, Jeong JH, Kim J. Enhanced cancer DNA vaccine via direct transfection to host dendritic cells recruited in injectable scaffolds. ACS Nano. 2020;14:11623\u201336.","journal-title":"ACS Nano"},{"issue":"12","key":"1628_CR145","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.3390\/bios12121130","volume":"12","author":"A Alnaimi","year":"2022","unstructured":"Alnaimi A, Al-Hamry A, Makableh Y, Adiraju A, Kanoun O. Gold nanoparticles-MWCNT based aptasensor for early diagnosis of prostate cancer. Biosensors. 2022;12(12):1130. https:\/\/doi.org\/10.3390\/bios12121130.","journal-title":"Biosensors"},{"issue":"1","key":"1628_CR146","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/md21010020","volume":"21","author":"N Gonz\u00e1lez-Ballesteros","year":"2022","unstructured":"Gonz\u00e1lez-Ballesteros N, Maietta I, Rey-M\u00e9ndez R, Rodr\u00edguez-Arg\u00fcelles MC, Lastra-Valdor M, Cavazza A, Grimaldi M, Bigi F, Sim\u00f3n-V\u00e1zquez R. Gold nanoparticles synthesized by an aqueous extract of codium tomentosum as potential antitumoral enhancers of gemcitabine. Mar Drugs. 2022;21(1):20.","journal-title":"Mar Drugs"},{"key":"1628_CR147","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/j.apsb.2022.08.024","volume":"13","author":"X Huang","year":"2023","unstructured":"Huang X, Sheng B, Tian H, Chen Q, Yang Y, Bui B, Pi J, Cai H, Chen S, Zhang J, Chen W, Zhou H, Sun P. Real-time SERS monitoring anticancer drug release along with SERS\/MR imaging for pH-sensitive chemo-phototherapy. Acta Pharm Sin B. 2023;13:1303\u201317.","journal-title":"Acta Pharm Sin B"},{"key":"1628_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.bios.2023.115847","volume":"245","author":"P Wang","year":"2023","unstructured":"Wang P, Liang Z, Li Z, Wang D, Ma Q. Plasmonic nanocavity-modulated electrochemiluminescence sensor for gastric cancer exosomal miRNA detection. Biosens Bioelectron. 2023;245: 115847.","journal-title":"Biosens Bioelectron"},{"issue":"7","key":"1628_CR149","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.3390\/ijms21072480","volume":"21","author":"X Bai","year":"2020","unstructured":"Bai X, Wang Y, Song Z, Feng Y, Chen Y, Zhang D, Feng L. The basic properties of gold nanoparticles and their applications in tumor diagnosis and treatment. Int J Mol Sci. 2020;21(7):2480.","journal-title":"Int J Mol Sci"},{"key":"1628_CR150","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.actbio.2021.07.047","volume":"134","author":"R Gonzalez-Pastor","year":"2021","unstructured":"Gonzalez-Pastor R, Hernandez Y, Gimeno M, de Martino A, Man YKS, Hallden G, Quintanilla M, de la Fuente JM, Martin-Duque P. Coating an adenovirus with functionalized gold nanoparticles favors uptake, intracellular trafficking and anti-cancer therapeutic efficacy. Acta Biomater. 2021;134:593\u2013604.","journal-title":"Acta Biomater"},{"key":"1628_CR151","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.drudis.2021.01.030","volume":"26","author":"XY Liu","year":"2021","unstructured":"Liu XY, Wang JQ, Ashby CR Jr, Zeng L, Fan YF, Chen ZS. Gold nanoparticles: synthesis, physiochemical properties and therapeutic applications in cancer. Drug Discov Today. 2021;26:1284\u201392.","journal-title":"Drug Discov Today"},{"key":"1628_CR152","doi-asserted-by":"publisher","first-page":"15741","DOI":"10.1038\/s41598-021-94983-y","volume":"11","author":"O Perzanowska","year":"2021","unstructured":"Perzanowska O, Majewski M, Strenkowska M, Glowala P, Czarnocki-Cieciura M, Mazur M, Kowalska J, Jemielity J. Nucleotide-decorated AuNPs as probes for nucleotide-binding proteins. Sci Rep. 2021;11:15741.","journal-title":"Sci Rep"},{"key":"1628_CR153","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.ijbiomac.2022.10.268","volume":"223","author":"Y Cai","year":"2022","unstructured":"Cai Y, Karmakar B, Babalghith AO, Batiha GE, AlSalem HS, El-Kott AF, Shati AA, Alfaifi MY, Elbehairi SEI. Decorated Au NPs on lignin coated magnetic nanoparticles: Investigation of its catalytic application in the reduction of aromatic nitro compounds and its performance against human lung cancer. Int J Biol Macromol. 2022;223:1067\u201382.","journal-title":"Int J Biol Macromol"},{"key":"1628_CR154","doi-asserted-by":"publisher","first-page":"8750","DOI":"10.1039\/D2TB01483A","volume":"10","author":"D Zhang","year":"2022","unstructured":"Zhang D, Liu P, Qin X, Cheng L, Wang F, Xiong X, Huang C, Zhang Z. HSA-templated self-generation of gold nanoparticles for tumor vaccine delivery and combinational therapy. J Mater Chem B. 2022;10:8750\u20139.","journal-title":"J Mater Chem B"},{"key":"1628_CR155","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0304-8853(99)00347-9","volume":"200","author":"RH Kodama","year":"1999","unstructured":"Kodama RH. Magnetic nanoparticles. J Magn Magn Mater. 1999;200:359\u201372.","journal-title":"J Magn Magn Mater"},{"key":"1628_CR156","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1186\/s12951-021-01150-6","volume":"19","author":"M Darroudi","year":"2021","unstructured":"Darroudi M, Gholami M, Rezayi M, Khazaei M. An overview and bibliometric analysis on the colorectal cancer therapy by magnetic functionalized nanoparticles for the responsive and targeted drug delivery. J Nanobiotechnology. 2021;19:399.","journal-title":"J Nanobiotechnology"},{"issue":"10","key":"1628_CR157","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3390\/jfb14100514","volume":"14","author":"E Korakaki","year":"2023","unstructured":"Korakaki E, Simos YV, Karouta N, Spyrou K, Zygouri P, Gournis DP, Tsamis KI, Stamatis H, Dounousi E, Vezyraki P, Peschos D. Effect of highly hydrophilic superparamagnetic iron oxide nanoparticles on macrophage function and survival. J Funct Biomat. 2023;14(10):514.","journal-title":"J Funct Biomat"},{"key":"1628_CR158","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2023.102713","volume":"54","author":"Y Peng","year":"2023","unstructured":"Peng Y, Li Y, Li L, Xie M, Wang Y, Butch CJ. Coating influence on inner shell water exchange: An underinvestigated major contributor to SPIONs relaxation properties. Nanomedicine. 2023;54: 102713.","journal-title":"Nanomedicine"},{"key":"1628_CR159","doi-asserted-by":"publisher","first-page":"1223695","DOI":"10.3389\/fimmu.2023.1223695","volume":"14","author":"F Pfister","year":"2023","unstructured":"Pfister F, Dorrie J, Schaft N, Buchele V, Unterweger H, Carnell LR, Schreier P, Stein R, Kubankova M, Guck J, Hackstein H, Alexiou C, Janko C. Human T cells loaded with superparamagnetic iron oxide nanoparticles retain antigen-specific TCR functionality. Front Immunol. 2023;14:1223695.","journal-title":"Front Immunol"},{"issue":"21","key":"1628_CR160","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.3390\/nano13212887","volume":"13","author":"M Sell","year":"2023","unstructured":"Sell M, Lopes AR, Escudeiro M, Esteves B, Monteiro AR, Trindade T, Cruz-Lopes L. Application of nanoparticles in cancer treatment: a concise review. Nanomaterials. 2023;13(21):2887.","journal-title":"Nanomaterials"},{"key":"1628_CR161","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphotobiol.2023.112797","volume":"248","author":"N Verimli","year":"2023","unstructured":"Verimli N, Gorali SI, Abisoglu B, Altan CL, Sucu BO, Karatas E, Tulek A, Bayraktaroglu C, Beker MC, Erdem SS. Development of light and pH-dual responsive self-quenching theranostic SPION to make EGFR overexpressing micro tumors glow and destroy. J Photochem Photobiol B. 2023;248: 112797.","journal-title":"J Photochem Photobiol B"},{"issue":"1","key":"1628_CR162","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/nano13010014","volume":"13","author":"L Zschiesche","year":"2022","unstructured":"Zschiesche L, Janko C, Friedrich B, Frey B, Band J, Lyer S, Alexiou C, Unterweger H. Biocompatibility of Dextran-Coated 30 nm and 80 nm Sized SPIONs towards monocytes, dendritic cells and lymphocytes. Nanomaterials. 2022;13(1):14.","journal-title":"Nanomaterials"},{"key":"1628_CR163","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1021\/acs.molpharmaceut.7b01103","volume":"15","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Zhao X, Cheng Y, Guo X, Yuan W. Iron oxide nanoparticles-based vaccine delivery for cancer treatment. Mol Pharm. 2018;15:1791\u20139.","journal-title":"Mol Pharm"},{"key":"1628_CR164","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12951-019-0520-0","volume":"17","author":"L Sanz-Ortega","year":"2019","unstructured":"Sanz-Ortega L, Portilla Y, Perez-Yague S, Barber DF. Magnetic targeting of adoptively transferred tumour-specific nanoparticle-loaded CD8(+) T cells does not improve their tumour infiltration in a mouse model of cancer but promotes the retention of these cells in tumour-draining lymph nodes. J Nanobiotechnology. 2019;17:87.","journal-title":"J Nanobiotechnology"},{"issue":"11","key":"1628_CR165","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.3390\/pharmaceutics14112388","volume":"14","author":"AM Dias","year":"2022","unstructured":"Dias AM, Courteau A, Bellaye PS, Kohli E, Oudot A, Doulain PE, Petitot C, Walker PM, Decr\u00e9au R, Collin B. Superparamagnetic iron oxide nanoparticles for immunotherapy of cancers through macrophages and magnetic hyperthermia. Pharmaceutics. 2022;14(11):2388.","journal-title":"Pharmaceutics"},{"key":"1628_CR166","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s12633-022-01962-7","volume":"15","author":"MM Fathy","year":"2022","unstructured":"Fathy MM, Yassin FM, Elshemey WM, Fahmy HM. Insight on the dependence of the drug delivery applications of mesoporous silica nanoparticles on their physical properties. SILICON. 2022;15:61\u201370.","journal-title":"SILICON"},{"issue":"12","key":"1628_CR167","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.3390\/pharmaceutics13122033","volume":"13","author":"E \u00c1lvarez","year":"2021","unstructured":"\u00c1lvarez E, Gonz\u00e1lez B, Lozano D, Doadrio AL, Colilla M, Izquierdo-Barba I. Nanoantibiotics based in mesoporous silica nanoparticles: new formulations for bacterial infection treatment. Pharmaceutics. 2021;13(12):2033.","journal-title":"Pharmaceutics"},{"issue":"1","key":"1628_CR168","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3390\/pharmaceutics15010089","volume":"15","author":"Y Huang","year":"2022","unstructured":"Huang Y, Du Z, Bao G, Fang G, Cappadona M, McClements L, Tuch BE, Lu H, Xu X. Smart drug-delivery system of upconversion nanoparticles coated with mesoporous silica for controlled release. Pharmaceutics. 2022;15(1):89.","journal-title":"Pharmaceutics"},{"issue":"16","key":"1628_CR169","doi-asserted-by":"publisher","first-page":"2307310","DOI":"10.1002\/smll.202307310","volume":"20","author":"X Chang","year":"2024","unstructured":"Chang X, Zhu Z, Weng L, Tang X, Liu T, Zhu M, Liu J, Tang W, Zhang Y, Chen X. Selective manipulation of the mitochondria oxidative stress in different cells using intelligent mesoporous silica nanoparticles to activate on-demand immunotherapy for cancer treatment. Small. 2024;20(16):2307310.","journal-title":"Small"},{"key":"1628_CR170","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41392-023-01654-7","volume":"8","author":"B Xu","year":"2023","unstructured":"Xu B, Li S, Shi R, Liu H. Multifunctional mesoporous silica nanoparticles for biomedical applications. Signal Transduct Target Ther. 2023;8:435.","journal-title":"Signal Transduct Target Ther"},{"key":"1628_CR171","doi-asserted-by":"publisher","first-page":"34658","DOI":"10.1021\/acsami.0c09484","volume":"12","author":"JY Lee","year":"2020","unstructured":"Lee JY, Kim MK, Nguyen TL, Kim J. Hollow mesoporous silica nanoparticles with extra-large mesopores for enhanced cancer vaccine. ACS Appl Mater Interfaces. 2020;12:34658\u201366.","journal-title":"ACS Appl Mater Interfaces"},{"key":"1628_CR172","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1021\/acscentsci.8b00035","volume":"4","author":"BG Cha","year":"2018","unstructured":"Cha BG, Jeong JH, Kim J. Extra-large pore mesoporous silica nanoparticles enabling co-delivery of high amounts of protein antigen and toll-like receptor 9 agonist for enhanced cancer vaccine efficacy. ACS Cent Sci. 2018;4:484\u201392.","journal-title":"ACS Cent Sci"},{"key":"1628_CR173","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202108012","volume":"34","author":"J Li","year":"2022","unstructured":"Li J, Huang D, Cheng R, Figueiredo P, Fontana F, Correia A, Wang S, Liu Z, Kemell M, Torrieri G, Makila EM, Salonen JJ, Hirvonen J, Gao Y, Li J, Luo Z, Santos HA, Xia B. Multifunctional biomimetic nanovaccines based on photothermal and weak-immunostimulatory nanoparticulate cores for the immunotherapy of solid tumors. Adv Mater. 2022;34: e2108012.","journal-title":"Adv Mater"},{"key":"1628_CR174","doi-asserted-by":"publisher","first-page":"13685","DOI":"10.1021\/acsanm.1c03245","volume":"5","author":"SC Burkert","year":"2022","unstructured":"Burkert SC, He X, Shurin GV, Nefedova Y, Kagan VE, Shurin MR, Star A. Nitrogen-doped carbon nanotube cups for cancer therapy. ACS Appl Nano Mater. 2022;5:13685\u201396.","journal-title":"ACS Appl Nano Mater"},{"key":"1628_CR175","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s12951-023-02030-x","volume":"21","author":"E Quagliarini","year":"2023","unstructured":"Quagliarini E, Pozzi D, Cardarelli F, Caracciolo G. The influence of protein corona on graphene oxide: implications for biomedical theranostics. J Nanobiotechnology. 2023;21:267.","journal-title":"J Nanobiotechnology"},{"key":"1628_CR176","doi-asserted-by":"publisher","first-page":"6147","DOI":"10.1039\/D3TB00595J","volume":"11","author":"X Song","year":"2023","unstructured":"Song X, Zhang C, Xing M, He C, Wang D, Chong L, Zhang X, Chen M, Li J. Immunological gadolinium-doped mesoporous carbon nanoparticles for tumor-targeted MRI and photothermal-immune co-therapy. J Mater Chem B. 2023;11:6147\u201358.","journal-title":"J Mater Chem B"},{"key":"1628_CR177","doi-asserted-by":"publisher","first-page":"6503","DOI":"10.2147\/IJN.S431061","volume":"18","author":"M Zeng","year":"2023","unstructured":"Zeng M, Wang Y, Liu M, Wei Y, Wen J, Zhang Y, Chen T, He N, Fan P, Dai X. Potential efficacy of herbal medicine-derived carbon dots in the treatment of diseases: from mechanism to clinic. Int J Nanomedicine. 2023;18:6503\u201325.","journal-title":"Int J Nanomedicine"},{"key":"1628_CR178","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.jconrel.2023.08.008","volume":"361","author":"H Kim","year":"2023","unstructured":"Kim H, Kim KS, Na K. Nanoparticle platform comprising lipid-tailed pH-sensitive carbon dots with minimal drug loss. J Control Release. 2023;361:373\u201384.","journal-title":"J Control Release"},{"key":"1628_CR179","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.ejps.2011.10.012","volume":"44","author":"T Wang","year":"2011","unstructured":"Wang T, Zou M, Jiang H, Ji Z, Gao P, Cheng G. Synthesis of a novel kind of carbon nanoparticle with large mesopores and macropores and its application as an oral vaccine adjuvant. Eur J Pharm Sci. 2011;44:653\u20139.","journal-title":"Eur J Pharm Sci"},{"key":"1628_CR180","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jconrel.2022.09.052","volume":"351","author":"E Elhassan","year":"2022","unstructured":"Elhassan E, Devnarain N, Mohammed M, Govender T, Omolo CA. Engineering hybrid nanosystems for efficient and targeted delivery against bacterial infections. J Control Release. 2022;351:598\u2013622.","journal-title":"J Control Release"},{"issue":"38","key":"1628_CR181","doi-asserted-by":"publisher","first-page":"eadn3002","DOI":"10.1126\/sciadv.adn3002","volume":"10","author":"J Li","year":"2024","unstructured":"Li J, Tianze W, Wang W, Gong Y, Mingzhu L, Zhang M, Wanyue L, Zhou Y, Yang Y. Hybrid nanoparticle\u2013mediated simultaneous ROS scavenging and STING activation improve the antitumor immunity of in situ vaccines. Sci Adv. 2024;10(38):eadn3002. https:\/\/doi.org\/10.1126\/sciadv.adn3002.","journal-title":"Sci Adv"},{"key":"1628_CR182","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1002\/cmdc.202000263","volume":"15","author":"Q Chen","year":"2020","unstructured":"Chen Q, Chen Y, Zhang W, Huang Q, Hu M, Peng D, Peng C, Wang L, Chen W. Acidity and glutathione dual-responsive polydopamine-coated organic-inorganic hybrid hollow mesoporous silica nanoparticles for controlled drug delivery. ChemMedChem. 2020;15:1940\u20136.","journal-title":"ChemMedChem"},{"key":"1628_CR183","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jconrel.2016.02.035","volume":"228","author":"X Zhuang","year":"2016","unstructured":"Zhuang X, Wu T, Zhao Y, Hu X, Bao Y, Guo Y, Song Q, Li G, Tan S, Zhang Z. Lipid-enveloped zinc phosphate hybrid nanoparticles for codelivery of H-2K(b) and H-2D(b)-restricted antigenic peptides and monophosphoryl lipid A to induce antitumor immunity against melanoma. J Control Release. 2016;228:26\u201337.","journal-title":"J Control Release"},{"key":"1628_CR184","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.jconrel.2020.09.012","volume":"327","author":"P Dash","year":"2020","unstructured":"Dash P, Piras AM, Dash M. Cell membrane coated nanocarriers - an efficient biomimetic platform for targeted therapy. J Control Release. 2020;327:546\u201370.","journal-title":"J Control Release"},{"key":"1628_CR185","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-022-00699-x","volume":"20","author":"RH Fang","year":"2023","unstructured":"Fang RH, Gao W, Zhang L. Targeting drugs to tumours using cell membrane-coated nanoparticles. Nat Rev Clin Oncol. 2023;20:33\u201348.","journal-title":"Nat Rev Clin Oncol"},{"key":"1628_CR186","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1021\/nl500618u","volume":"14","author":"RH Fang","year":"2014","unstructured":"Fang RH, Hu CM, Luk BT, Gao W, Copp JA, Tai Y, O\u2019Connor DE, Zhang L. Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett. 2014;14:2181\u20138.","journal-title":"Nano Lett"},{"key":"1628_CR187","first-page":"299","volume":"21","author":"Z Li","year":"2023","unstructured":"Li Z, Cai H, Li Z, Ren L, Ma X, Zhu H, Gong Q, Zhang H, Gu Z, Luo K. A tumor cell membrane-coated self-amplified nanosystem as a nanovaccine to boost the therapeutic effect of anti-PD-L1 antibody. Bioact Mater. 2023;21:299\u2013312.","journal-title":"Bioact Mater"},{"key":"1628_CR188","doi-asserted-by":"publisher","first-page":"1238649","DOI":"10.3389\/fimmu.2023.1238649","volume":"14","author":"F Zhou","year":"2023","unstructured":"Zhou F, Zhang D. Recent advance in the development of tuberculosis vaccines in clinical trials and virus-like particle-based vaccine candidates. Front Immunol. 2023;14:1238649.","journal-title":"Front Immunol"},{"key":"1628_CR189","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2221859120","volume":"120","author":"YH Chung","year":"2023","unstructured":"Chung YH, Ortega-Rivera OA, Volckaert BA, Jung E, Zhao Z, Steinmetz NF. Viral nanoparticle vaccines against S100A9 reduce lung tumor seeding and metastasis. Proc Natl Acad Sci U S A. 2023;120: e2221859120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1628_CR190","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3390\/genes14020259","volume":"14","author":"H Fujita","year":"2023","unstructured":"Fujita H, Ohta S, Nakamura N, Somiya M, Horie M. Progress of endogenous and exogenous nanoparticles for cancer therapy and diagnostics. Genes. 2023;14(2):259. https:\/\/doi.org\/10.3390\/genes14020259.","journal-title":"Genes"},{"key":"1628_CR191","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41392-020-00261-0","volume":"5","author":"J Dai","year":"2020","unstructured":"Dai J, Su Y, Zhong S, Cong L, Liu B, Yang J, Tao Y, He Z, Chen C, Jiang Y. Exosomes: key players in cancer and potential therapeutic strategy. Signal Transduct Target Ther. 2020;5:145.","journal-title":"Signal Transduct Target Ther"},{"key":"1628_CR192","doi-asserted-by":"publisher","first-page":"6478","DOI":"10.1126\/science.aau6977","volume":"367","author":"R Kalluri","year":"2020","unstructured":"Kalluri R, LeBleu VS. The biology, function and biomedical applications of exosomes. Science. 2020;367:6478. https:\/\/doi.org\/10.1126\/science.aau6977.","journal-title":"Science"},{"key":"1628_CR193","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13045-019-0739-0","volume":"12","author":"Q Wu","year":"2019","unstructured":"Wu Q, Zhou L, Lv D, Zhu X, Tang H. Exosome-mediated communication in the tumor microenvironment contributes to hepatocellular carcinoma development and progression. J Hematol Oncol. 2019;12:53.","journal-title":"J Hematol Oncol"},{"key":"1628_CR194","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1039\/C9TB00170K","volume":"7","author":"M Zhang","year":"2019","unstructured":"Zhang M, Zang X, Wang M, Li Z, Qiao M, Hu H, Chen D. Exosome-based nanocarriers as bio-inspired and versatile vehicles for drug delivery: recent advances and challenges. J Mater Chem B. 2019;7:2421\u201333.","journal-title":"J Mater Chem B"},{"key":"1628_CR195","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13045-022-01266-8","volume":"15","author":"B Zuo","year":"2022","unstructured":"Zuo B, Zhang Y, Zhao K, Wu L, Qi H, Yang R, Gao X, Geng M, Wu Y, Jing R, Zhou Q, Seow Y, Yin H. Universal immunotherapeutic strategy for hepatocellular carcinoma with exosome vaccines that engage adaptive and innate immune responses. J Hematol Oncol. 2022;15:46.","journal-title":"J Hematol Oncol"},{"key":"1628_CR196","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12941-023-00645-4","volume":"22","author":"L Yao","year":"2023","unstructured":"Yao L, Wei B, Wang Y, Xu B, Yang M, Chen X, Chen F. A critical role of outer membrane vesicles in antibiotic resistance in carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob. 2023;22:95.","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"1628_CR197","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","volume":"21","author":"M Saxena","year":"2021","unstructured":"Saxena M, van der Burg SH, Melief CJM, Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer. 2021;21:360\u201378.","journal-title":"Nat Rev Cancer"},{"key":"1628_CR198","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202104849","volume":"33","author":"L Ma","year":"2021","unstructured":"Ma L, Diao L, Peng Z, Jia Y, Xie H, Li B, Ma J, Zhang M, Cheng L, Ding D, Zhang X, Chen H, Mo F, Jiang H, Xu G, Meng F, Zhong Z, Liu M. Immunotherapy and prevention of cancer by nanovaccines loaded with whole-cell components of tumor tissues or cells. Adv Mater. 2021;33: e2104849.","journal-title":"Adv Mater"},{"key":"1628_CR199","doi-asserted-by":"publisher","first-page":"8291","DOI":"10.1021\/acsabm.1c00828","volume":"4","author":"C Berti","year":"2021","unstructured":"Berti C, Boarino A, Graciotti M, Bader LPE, Kandalaft LE, Klok HA. Reduction-sensitive protein nanogels enhance uptake of model and tumor lysate antigens in vitro by mouse- and human-derived dendritic cells. ACS Appl Bio Mater. 2021;4:8291\u2013300.","journal-title":"ACS Appl Bio Mater"},{"key":"1628_CR200","doi-asserted-by":"publisher","DOI":"10.1002\/mabi.202100356","volume":"22","author":"C Berti","year":"2022","unstructured":"Berti C, Graciotti M, Boarino A, Yakkala C, Kandalaft LE, Klok HA. Polymer nanoparticle-mediated delivery of oxidized tumor lysate-based cancer vaccines. Macromol Biosci. 2022;22: e2100356.","journal-title":"Macromol Biosci"},{"key":"1628_CR201","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/advs.201900069","volume":"7","author":"HC Chang","year":"2020","unstructured":"Chang HC, Zou ZZ, Wang QH, Li J, Jin H, Yin QX, Xing D. Targeting and specific activation of antigen-presenting cells by endogenous antigen-loaded nanoparticles elicits tumor-specific immunity advanced. Science. 2020;7:1. https:\/\/doi.org\/10.1002\/advs.201900069.","journal-title":"Science"},{"issue":"3","key":"1628_CR202","doi-asserted-by":"publisher","first-page":"e163449","DOI":"10.1172\/JCI163449","volume":"133","author":"C Lee-Chang","year":"2023","unstructured":"Lee-Chang C, Lesniak MS. Next-generation antigen-presenting cell immune therapeutics for gliomas. J Clinic Invest. 2023;133(3):e163449. https:\/\/doi.org\/10.1172\/JCI163449.","journal-title":"J Clinic Invest"},{"key":"1628_CR203","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.tibtech.2014.06.007","volume":"32","author":"LJ Eggermont","year":"2014","unstructured":"Eggermont LJ, Paulis LE, Tel J, Figdor CG. Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells. Trends Biotechnol. 2014;32:456\u201365.","journal-title":"Trends Biotechnol"},{"key":"1628_CR204","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41596-019-0249-0","volume":"15","author":"DKY Zhang","year":"2020","unstructured":"Zhang DKY, Cheung AS, Mooney DJ. Activation and expansion of human T cells using artificial antigen-presenting cell scaffolds. Nat Protoc. 2020;15:773\u201398.","journal-title":"Nat Protoc"},{"key":"1628_CR205","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1158\/2159-8290.CD-20-1211","volume":"11","author":"P Dey","year":"2021","unstructured":"Dey P, Kimmelman AC, DePinho RA. Metabolic codependencies in the tumor microenvironment. Cancer Discov. 2021;11:1067\u201381.","journal-title":"Cancer Discov"},{"key":"1628_CR206","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s42255-020-00317-z","volume":"3","author":"I Elia","year":"2021","unstructured":"Elia I, Haigis MC. Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism. Nat Metab. 2021;3:21\u201332.","journal-title":"Nat Metab"},{"key":"1628_CR207","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1038\/s41423-020-0365-3","volume":"18","author":"N Dumauthioz","year":"2021","unstructured":"Dumauthioz N, Tschumi B, Wenes M, Marti B, Wang H, Franco F, Li W, Lopez-Mejia IC, Fajas L, Ho PC, Donda A, Romero P, Zhang L. Enforced PGC-1alpha expression promotes CD8 T cell fitness, memory formation and antitumor immunity. Cell Mol Immunol. 2021;18:1761\u201371.","journal-title":"Cell Mol Immunol"},{"key":"1628_CR208","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1158\/0008-5472.CAN-21-0052","volume":"81","author":"A Chekaoui","year":"2021","unstructured":"Chekaoui A, Ertl HCJ. PPARalpha agonist fenofibrate enhances cancer vaccine efficacy. Cancer Res. 2021;81:4431\u201340.","journal-title":"Cancer Res"},{"key":"1628_CR209","doi-asserted-by":"publisher","first-page":"24947","DOI":"10.1021\/acsnano.3c06784","volume":"17","author":"YT Qin","year":"2023","unstructured":"Qin YT, Liu XH, An JX, Liang JL, Li CX, Jin XK, Ji P, Zhang XZ. Dendritic cell-based in situ nanovaccine for reprogramming lipid metabolism to boost tumor immunotherapy. ACS Nano. 2023;17:24947\u201360.","journal-title":"ACS Nano"},{"key":"1628_CR210","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1016\/j.apsb.2023.08.028","volume":"13","author":"L Guo","year":"2023","unstructured":"Guo L, Ding J, Zhou W. Converting bacteria into autologous tumor vaccine via surface biomineralization of calcium carbonate for enhanced immunotherapy. Acta Pharm Sin B. 2023;13:5074\u201390.","journal-title":"Acta Pharm Sin B"},{"key":"1628_CR211","doi-asserted-by":"publisher","first-page":"1286750","DOI":"10.3389\/fimmu.2023.1286750","volume":"14","author":"AL Portillo","year":"2023","unstructured":"Portillo AL, Monteiro JK, Rojas EA, Ritchie TM, Gillgrass A, Ashkar AA. Charting a killer course to the solid tumor: strategies to recruit and activate NK cells in the tumor microenvironment. Front Immunol. 2023;14:1286750.","journal-title":"Front Immunol"},{"issue":"8","key":"1628_CR212","doi-asserted-by":"publisher","first-page":"e2301326","DOI":"10.1002\/smtd.202301326","volume":"8","author":"X Huang","year":"2023","unstructured":"Huang X, Zhang W. Overcoming T cell exhaustion in tumor microenvironment via immune checkpoint modulation with nano\u2010delivery systems for enhanced immunotherapy. Small Methods. 2023;8(8):e2301326. https:\/\/doi.org\/10.1002\/smtd.202301326.","journal-title":"Small Methods"},{"key":"1628_CR213","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12943-023-01885-w","volume":"22","author":"M Yi","year":"2023","unstructured":"Yi M, Li T, Niu M, Mei Q, Zhao B, Chu Q, Dai Z, Wu K. Exploiting innate immunity for cancer immunotherapy. Mol Cancer. 2023;22:187.","journal-title":"Mol Cancer"},{"key":"1628_CR214","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20:651\u201368.","journal-title":"Nat Rev Immunol"},{"key":"1628_CR215","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.120678","volume":"270","author":"L Luo","year":"2021","unstructured":"Luo L, Li X, Zhang J, Zhu C, Jiang M, Luo Z, Qin B, Wang Y, Chen B, Du Y, Lou Y, You J. Enhanced immune memory through a constant photothermal-metabolism regulation for cancer prevention and treatment. Biomaterials. 2021;270: 120678.","journal-title":"Biomaterials"},{"key":"1628_CR216","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.11.026","author":"M-T Purde","year":"2023","unstructured":"Purde M-T, Cupovic J, Palmowski YA, Makky A, Schmidt S, Rochwarger A, Hartmann F, Stemeseder F, Lercher A, Abdou M-T, Bomze D, Besse L, Berner F, T\u00fcting T, H\u00f6lzel M, Bergthaler A, Kochanek S, Ludewig B, Lauterbach H, Orlinger KK, Bald T, Schietinger A, Sch\u00fcrch C, Ring SS, Flatz L. A replicating LCMV-based vaccine for the treatment of solid tumors. Mol Therapy. 2023. https:\/\/doi.org\/10.1016\/j.ymthe.2023.11.026.","journal-title":"Mol Therapy"},{"key":"1628_CR217","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.actbio.2023.07.059","volume":"169","author":"S Ma","year":"2023","unstructured":"Ma S, Li X, Mai Y, Guo J, Zuo W, Yang J. Immunotherapeutic treatment of lung cancer and bone metastasis with a mPLA\/mRNA tumor vaccine. Acta Biomater. 2023;169:489\u201399.","journal-title":"Acta Biomater"},{"key":"1628_CR218","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/advs.202305081","volume":"11","author":"Z Chen","year":"2024","unstructured":"Chen Z, Yong T, Wei Z, Zhang X, Li X, Qin J, Li J, Hu J, Yang X, Gan L. Engineered probiotic-based personalized cancer vaccine potentiates antitumor immunity through initiating trained immunity. Adv Sci. 2024;11:3. https:\/\/doi.org\/10.1002\/advs.202305081.","journal-title":"Adv Sci"},{"issue":"2","key":"1628_CR219","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3390\/vaccines8020317","volume":"8","author":"P Kadam","year":"2020","unstructured":"Kadam P, Sharma S. PD-1 immune checkpoint blockade promotes therapeutic cancer vaccine to eradicate lung cancer. Vaccines. 2020;8(2):317. https:\/\/doi.org\/10.3390\/vaccines8020317.","journal-title":"Vaccines"},{"key":"1628_CR220","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.189020","volume":"1878","author":"RN Gacche","year":"2023","unstructured":"Gacche RN. Changing landscape of anti-angiogenic therapy: Novel approaches and clinical perspectives. Biochim Biophys Acta Rev Cancer. 2023;1878: 189020.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1628_CR221","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12943-023-01865-0","volume":"22","author":"M Chehelgerdi","year":"2023","unstructured":"Chehelgerdi M, Chehelgerdi M, Allela OQB, Pecho RDC, Jayasankar N, Rao DP, Thamaraikani T, Vasanthan M, Viktor P, Lakshmaiya N, Saadh MJ, Amajd A, Abo-Zaid MA, Castillo-Acobo RY, Ismail AH, Amin AH, Akhavan-Sigari R. Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. Mol Cancer. 2023;22:169.","journal-title":"Mol Cancer"},{"key":"1628_CR222","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41392-023-01536-y","volume":"8","author":"D Fan","year":"2023","unstructured":"Fan D, Cao Y, Cao M, Wang Y, Cao Y, Gong T. Nanomedicine in cancer therapy. Signal Transduct Target Ther. 2023;8:293.","journal-title":"Signal Transduct Target Ther"},{"key":"1628_CR223","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","volume":"8","author":"ZL Liu","year":"2023","unstructured":"Liu ZL, Chen HH, Zheng LL, Sun LP, Shi L. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther. 2023;8:198.","journal-title":"Signal Transduct Target Ther"},{"key":"1628_CR224","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","volume":"77","author":"R Lugano","year":"2020","unstructured":"Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci. 2020;77:1745\u201370.","journal-title":"Cell Mol Life Sci"},{"key":"1628_CR225","doi-asserted-by":"publisher","first-page":"7940","DOI":"10.1021\/acsnano.9b08460","volume":"14","author":"N Huang","year":"2020","unstructured":"Huang N, Liu Y, Fang Y, Zheng S, Wu J, Wang M, Zhong W, Shi M, Xing M, Liao W. Gold nanoparticles induce tumor vessel normalization and impair metastasis by inhibiting endothelial smad2\/3 signaling. ACS Nano. 2020;14:7940\u201358.","journal-title":"ACS Nano"},{"key":"1628_CR226","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s00262-015-1747-8","volume":"64","author":"S Ugel","year":"2015","unstructured":"Ugel S, Facciponte JG, De Sanctis F, Facciabene A. Targeting tumor vasculature: expanding the potential of DNA cancer vaccines. Cancer Immunol Immunother. 2015;64:1339\u201348.","journal-title":"Cancer Immunol Immunother"},{"key":"1628_CR227","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/s41586-023-06740-y","volume":"623","author":"N Bansaccal","year":"2023","unstructured":"Bansaccal N, Vieugue P, Sarate R, Song Y, Minguijon E, Miroshnikova YA, Zeuschner D, Collin A, Allard J, Engelman D, Delaunois AL, Liagre M, de Groote L, Timmerman E, Van Haver D, Impens F, Salmon I, Wickstrom SA, Sifrim A, Blanpain C. The extracellular matrix dictates regional competence for tumour initiation. Nature. 2023;623:828\u201335.","journal-title":"Nature"},{"key":"1628_CR228","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-023-01744-8","volume":"22","author":"Z Yuan","year":"2023","unstructured":"Yuan Z, Li Y, Zhang S, Wang X, Dou H, Yu X, Zhang Z, Yang S, Xiao M. Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. Mol Cancer. 2023;22:48.","journal-title":"Mol Cancer"},{"key":"1628_CR229","doi-asserted-by":"publisher","first-page":"1093990","DOI":"10.3389\/fimmu.2022.1093990","volume":"13","author":"L He","year":"2022","unstructured":"He L, Kang Q, Chan KI, Zhang Y, Zhong Z, Tan W. The immunomodulatory role of matrix metalloproteinases in colitis-associated cancer. Front Immunol. 2022;13:1093990.","journal-title":"Front Immunol"},{"key":"1628_CR230","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1186\/s12967-023-04714-2","volume":"21","author":"W Zhang","year":"2023","unstructured":"Zhang W, Wang J, Liu C, Li Y, Sun C, Wu J, Wu Q. Crosstalk and plasticity driving between cancer-associated fibroblasts and tumor microenvironment: significance of breast cancer metastasis. J Transl Med. 2023;21:827.","journal-title":"J Transl Med"},{"key":"1628_CR231","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2020.120114","volume":"252","author":"Y Hu","year":"2020","unstructured":"Hu Y, Lin L, Chen J, Maruyama A, Tian H, Chen X. Synergistic tumor immunological strategy by combining tumor nanovaccine with gene-mediated extracellular matrix scavenger. Biomaterials. 2020;252: 120114.","journal-title":"Biomaterials"},{"key":"1628_CR232","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.critrevonc.2019.02.010","volume":"137","author":"G Gonzalez-Avila","year":"2019","unstructured":"Gonzalez-Avila G, Sommer B, Mendoza-Posada DA, Ramos C, Garcia-Hernandez AA, Falfan-Valencia R. Matrix metalloproteinases participation in the metastatic process and their diagnostic and therapeutic applications in cancer. Crit Rev Oncol Hematol. 2019;137:57\u201383.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1628_CR233","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.7150\/thno.23209","volume":"8","author":"Y Lv","year":"2018","unstructured":"Lv Y, Zhao X, Zhu L, Li S, Xiao Q, He W, Yin L. Targeting intracellular MMPs efficiently inhibits tumor metastasis and angiogenesis. Theranostics. 2018;8:2830\u201345.","journal-title":"Theranostics"},{"issue":"1","key":"1628_CR234","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1152\/physrev.00048.2019","volume":"101","author":"G Biffi","year":"2021","unstructured":"Biffi G, Tuveson DA. Diversity and biology of cancer-associated fibroblasts. Physiol Rev. 2021;101(1):147\u201376. https:\/\/doi.org\/10.1152\/physrev.00048.2019.","journal-title":"Physiol Rev"},{"key":"1628_CR235","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ijc.32193","volume":"146","author":"M Nurmik","year":"2020","unstructured":"Nurmik M, Ullmann P, Rodriguez F, Haan S, Letellier E. In search of definitions: cancer-associated fibroblasts and their markers. Int J Cancer. 2020;146:895\u2013905.","journal-title":"Int J Cancer"},{"issue":"3","key":"1628_CR236","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"20","author":"E Sahai","year":"2020","unstructured":"Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, Fearon D, Greten FR, Hingorani SR, Hunter T, Hynes RO. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20(3):174\u201386.","journal-title":"Nat Rev Cancer"},{"key":"1628_CR237","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.biomaterials.2018.01.014","volume":"159","author":"J Zhao","year":"2018","unstructured":"Zhao J, Wang H, Hsiao CH, Chow DS, Koay EJ, Kang Y, Wen X, Huang Q, Ma Y, Bankson JA, Ullrich SE, Overwijk W, Maitra A, Piwnica-Worms D, Fleming JB, Li C. Simultaneous inhibition of hedgehog signaling and tumor proliferation remodels stroma and enhances pancreatic cancer therapy. Biomaterials. 2018;159:215\u201328.","journal-title":"Biomaterials"},{"key":"1628_CR238","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.613534","volume":"9","author":"Z Wang","year":"2021","unstructured":"Wang Z, Yang Q, Tan Y, Tang Y, Ye J, Yuan B, Yu W. Cancer-associated fibroblasts suppress cancer development: the other side of the coin. Front Cell Dev Biol. 2021;9: 613534.","journal-title":"Front Cell Dev Biol"},{"key":"1628_CR239","doi-asserted-by":"publisher","first-page":"12357","DOI":"10.1021\/acsnano.9b04857","volume":"13","author":"J Lang","year":"2019","unstructured":"Lang J, Zhao X, Qi Y, Zhang Y, Han X, Ding Y, Guan J, Ji T, Zhao Y, Nie G. Reshaping prostate tumor microenvironment to suppress metastasis via cancer-associated fibroblast inactivation with peptide-assembly-based nanosystem. ACS Nano. 2019;13:12357\u201371.","journal-title":"ACS Nano"},{"key":"1628_CR240","doi-asserted-by":"publisher","first-page":"10337","DOI":"10.1021\/acsnano.3c00764","volume":"17","author":"H Shin","year":"2023","unstructured":"Shin H, Kim Y, Jon S. Nanovaccine displaying immunodominant T cell epitopes of fibroblast activation protein is effective against desmoplastic tumors. ACS Nano. 2023;17:10337\u201352.","journal-title":"ACS Nano"},{"issue":"11","key":"1628_CR241","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.3390\/biom13111604","volume":"13","author":"HI Atiya","year":"2023","unstructured":"Atiya HI, Gorecki G, Garcia GL, Frisbie LG, Baruwal R, Coffman L. Stromal-modulated epithelial-to-mesenchymal transition in cancer cells. Biomolecules. 2023;13(11):1604.","journal-title":"Biomolecules"},{"issue":"11","key":"1628_CR242","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.3390\/genes14112001","volume":"14","author":"L Li","year":"2023","unstructured":"Li L, Zheng J, Oltean S. Regulation of epithelial-mesenchymal transitions by alternative splicing: potential new area for cancer therapeutics. Genes. 2023;14(11):2001.","journal-title":"Genes"},{"key":"1628_CR243","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.semcancer.2023.11.009","volume":"97","author":"H Schuhwerk","year":"2023","unstructured":"Schuhwerk H, Brabletz T. Mutual regulation of TGFbeta-induced oncogenic EMT, cell cycle progression and the DDR. Semin Cancer Biol. 2023;97:86\u2013103.","journal-title":"Semin Cancer Biol"},{"key":"1628_CR244","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.tcb.2020.07.003","volume":"30","author":"B Bakir","year":"2020","unstructured":"Bakir B, Chiarella AM, Pitarresi JR, Rustgi AK. EMT, MET, plasticity, and tumor metastasis. Trends Cell Biol. 2020;30:764\u201376.","journal-title":"Trends Cell Biol"},{"key":"1628_CR245","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021108647","volume":"40","author":"S Brabletz","year":"2021","unstructured":"Brabletz S, Schuhwerk H, Brabletz T, Stemmler MP. Dynamic EMT: a multi-tool for tumor progression. EMBO J. 2021;40: e108647.","journal-title":"EMBO J"},{"key":"1628_CR246","first-page":"1299","volume":"44","author":"Y Lei","year":"2020","unstructured":"Lei Y, Chen L, Zhang G, Shan A, Ye C, Liang B, Sun J, Liao X, Zhu C, Chen Y, Wang J, Zhang E, Deng L. MicroRNAs target the Wnt\/beta-catenin signaling pathway to regulate epithelial-mesenchymal transition in cancer (Review). Oncol Rep. 2020;44:1299\u2013313.","journal-title":"Oncol Rep"},{"issue":"1","key":"1628_CR247","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.gendis.2023.01.030","volume":"11","author":"K Qin","year":"2024","unstructured":"Qin K, Yu M, Fan J, Wang H, Zhao P, Zhao G, Zeng W, Chen C, Wang Y, Wang A, Schwartz Z. Canonical and noncanonical Wnt signaling: Multilayered mediators, signaling mechanisms and major signaling crosstalk. Genes Diseases. 2024;11(1):103\u201334.","journal-title":"Genes Diseases"},{"key":"1628_CR248","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1038\/s41467-022-30063-7","volume":"13","author":"JR van Beijnum","year":"2022","unstructured":"van Beijnum JR, Huijbers EJM, van Loon K, Blanas A, Akbari P, Roos A, Wong TJ, Denisov SS, Hackeng TM, Jimenez CR, Nowak-Sliwinska P, Griffioen AW. Extracellular vimentin mimics VEGF and is a target for anti-angiogenic immunotherapy. Nat Commun. 2022;13:2842.","journal-title":"Nat Commun"},{"issue":"1","key":"1628_CR249","doi-asserted-by":"publisher","first-page":"7661","DOI":"10.1038\/s41467-023-43548-w","volume":"14","author":"S Shang","year":"2023","unstructured":"Shang S, Yang C, Chen F, Xiang RS, Zhang H, Dai SY, Liu J, Lv XX, Zhang C, Liu XT, Zhang Q. ID1 expressing macrophages support cancer cell stemness and limit CD8+ T cell infiltration in colorectal cancer. Nat Commun. 2023;14(1):7661.","journal-title":"Nat Commun"},{"issue":"1","key":"1628_CR250","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/s13046-023-02883-y","volume":"42","author":"Q Zheng","year":"2023","unstructured":"Zheng Q, Tang J, Aicher A, Bou Kheir T, Sabanovic B, Ananthanarayanan P, Reina C, Chen M, Gu JM, He B, Alcala S. Inhibiting NR5A2 targets stemness in pancreatic cancer by disrupting SOX2\/MYC signaling and restoring chemosensitivity. J Exp Clin Cancer Res. 2023;42(1):323.","journal-title":"J Exp Clin Cancer Res"},{"key":"1628_CR251","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nature14034","volume":"517","author":"AV Kurtova","year":"2015","unstructured":"Kurtova AV, Xiao J, Mo Q, Pazhanisamy S, Krasnow R, Lerner SP, Chen F, Roh TT, Lay E, Ho PL, Chan KS. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature. 2015;517:209\u201313.","journal-title":"Nature"},{"issue":"7","key":"1628_CR252","doi-asserted-by":"publisher","first-page":"1801987","DOI":"10.1002\/advs.201801987","volume":"6","author":"J Liu","year":"2019","unstructured":"Liu J, Chang B, Li Q, Luming X, Liu X, Wang G, Wang Z, Wang L. Redox\u2010responsive dual drug delivery nanosystem suppresses cancer repopulation by abrogating doxorubicin\u2010promoted cancer stemness, metastasis, and drug resistance. Adv Sci. 2019;6(7):1801987. https:\/\/doi.org\/10.1002\/advs.201801987.","journal-title":"Adv Sci"},{"key":"1628_CR253","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1158\/0008-5472.CAN-11-1400","volume":"72","author":"N Ning","year":"2012","unstructured":"Ning N, Pan Q, Zheng F, Teitz-Tennenbaum S, Egenti M, Yet J, Li M, Ginestier C, Wicha MS, Moyer JS, Prince ME, Xu Y, Zhang XL, Huang S, Chang AE, Li Q. Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res. 2012;72:1853\u201364.","journal-title":"Cancer Res"},{"key":"1628_CR254","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106631","volume":"85","author":"M Guo","year":"2020","unstructured":"Guo M, Luo B, Pan M, Li M, Zhao F, Dou J. MUC1 plays an essential role in tumor immunity of colorectal cancer stem cell vaccine. Int Immunopharmacol. 2020;85: 106631.","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"1628_CR255","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.3390\/cancers12061452","volume":"12","author":"SJP Pratt","year":"2020","unstructured":"Pratt SJP, Lee RM, Martin SS. The mechanical microenvironment in breast cancer. Cancers. 2020;12(6):1452. https:\/\/doi.org\/10.3390\/cancers12061452.","journal-title":"Cancers"},{"key":"1628_CR256","doi-asserted-by":"publisher","first-page":"44","DOI":"10.20892\/j.issn.2095-3941.2022.0491","volume":"20","author":"P Zhu","year":"2023","unstructured":"Zhu P, Lu H, Wang M, Chen K, Chen Z, Yang L. Targeted mechanical forces enhance the effects of tumor immunotherapy by regulating immune cells in the tumor microenvironment. Cancer Biol Med. 2023;20:44\u201355.","journal-title":"Cancer Biol Med"},{"key":"1628_CR257","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.7150\/thno.24821","volume":"8","author":"L Hou","year":"2018","unstructured":"Hou L, Liu Q, Shen L, Liu Y, Zhang X, Chen F, Huang L. Nano-delivery of fraxinellone remodels tumor microenvironment and facilitates therapeutic vaccination in desmoplastic melanoma. Theranostics. 2018;8:3781\u201396.","journal-title":"Theranostics"},{"key":"1628_CR258","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41392-021-00817-8","volume":"6","author":"D Lin","year":"2021","unstructured":"Lin D, Shen L, Luo M, Zhang K, Li J, Yang Q, Zhu F, Zhou D, Zheng S, Chen Y, Zhou J. Circulating tumor cells: biology and clinical significance. Signal Transduct Target Ther. 2021;6:404.","journal-title":"Signal Transduct Target Ther"},{"key":"1628_CR259","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1586\/14789450.4.6.741","volume":"4","author":"K Jacob","year":"2007","unstructured":"Jacob K, Sollier C, Jabado N. Circulating tumor cells: detection, molecular profiling and future prospects. Expert Rev Proteomics. 2007;4:741\u201356.","journal-title":"Expert Rev Proteomics"},{"key":"1628_CR260","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1200\/JCO.2007.15.8923","volume":"26","author":"SJ Cohen","year":"2008","unstructured":"Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:3213\u201321.","journal-title":"J Clin Oncol"},{"key":"1628_CR261","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1158\/1078-0432.CCR-06-1695","volume":"13","author":"S Riethdorf","year":"2007","unstructured":"Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B, Janni W, Coith C, Beck K, Janicke F, Jackson S, Gornet T, Cristofanilli M, Pantel K. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the Cell Search system. Clin Cancer Res. 2007;13:920\u20138.","journal-title":"Clin Cancer Res"},{"key":"1628_CR262","doi-asserted-by":"publisher","first-page":"11476","DOI":"10.1021\/acs.chemrev.7b00194","volume":"117","author":"C Kinnear","year":"2017","unstructured":"Kinnear C, Moore TL, Rodriguez-Lorenzo L, Rothen-Rutishauser B, Petri-Fink A. Form follows function: nanoparticle shape and its implications for nanomedicine. Chem Rev. 2017;117:11476\u2013521.","journal-title":"Chem Rev"},{"key":"1628_CR263","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nbt.3330","volume":"33","author":"E Blanco","year":"2015","unstructured":"Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33:941\u201351.","journal-title":"Nat Biotechnol"},{"key":"1628_CR264","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biomaterials.2016.10.033","volume":"113","author":"J Yao","year":"2017","unstructured":"Yao J, Feng J, Gao X, Wei D, Kang T, Zhu Q, Jiang T, Wei X, Chen J. Neovasculature and circulating tumor cells dual-targeting nanoparticles for the treatment of the highly-invasive breast cancer. Biomaterials. 2017;113:1\u201317.","journal-title":"Biomaterials"},{"key":"1628_CR265","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.jconrel.2012.02.018","volume":"160","author":"MJ Mitchell","year":"2012","unstructured":"Mitchell MJ, Chen CS, Ponmudi V, Hughes AD, King MR. E-selectin liposomal and nanotube-targeted delivery of doxorubicin to circulating tumor cells. J Control Release. 2012;160:609\u201317.","journal-title":"J Control Release"},{"key":"1628_CR266","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s43018-020-0076-9","volume":"1","author":"S Kaczanowska","year":"2020","unstructured":"Kaczanowska S, Kaplan RN. Mapping the switch that drives the pre-metastatic niche. Nat Cancer. 2020;1:577\u20139.","journal-title":"Nat Cancer"},{"key":"1628_CR267","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41590-021-00899-0","volume":"22","author":"C Marar","year":"2021","unstructured":"Marar C, Starich B, Wirtz D. Extracellular vesicles in immunomodulation and tumor progression. Nat Immunol. 2021;22:560\u201370.","journal-title":"Nat Immunol"},{"key":"1628_CR268","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1038\/s41467-020-18794-x","volume":"11","author":"J Winkler","year":"2020","unstructured":"Winkler J, Abisoye-Ogunniyan A, Metcalf KJ, Werb Z. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat Commun. 2020;11:5120.","journal-title":"Nat Commun"},{"key":"1628_CR269","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","volume":"6","author":"H Zhao","year":"2021","unstructured":"Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, Li Y. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021;6:263.","journal-title":"Signal Transduct Target Ther"},{"key":"1628_CR270","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12964-023-01413-9","volume":"22","author":"L Gong","year":"2024","unstructured":"Gong L, Li G, Yi X, Han Q, Wu Q, Ying F, Shen L, Cao Y, Liu X, Gao L, Li W, Wang Z, Cai J. Tumor-derived small extracellular vesicles facilitate omental metastasis of ovarian cancer by triggering activation of mesenchymal stem cells. Cell Commun Signal. 2024;22:47.","journal-title":"Cell Commun Signal"},{"key":"1628_CR271","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10606","volume":"9","author":"SM Orbach","year":"2024","unstructured":"Orbach SM, DeVaull CY, Bealer EJ, Ross BC, Jeruss JS, Shea LD. An engineered niche delineates metastatic potential of breast cancer. Bioeng Transl Med. 2024;9: e10606.","journal-title":"Bioeng Transl Med"},{"key":"1628_CR272","doi-asserted-by":"crossref","unstructured":"K. Wu, Y. Li, Y. Ji, C. Liu, X. Wang, H. Guo, J. Zhang, Y. He, Tumor-Derived RAB21+ABHD12+ sEVs Drive the Premetastatic Microenvironment in the Lung. Cancer Immunol Res, OF1-OF19 (2024).","DOI":"10.1158\/2326-6066.CIR-23-0221"},{"key":"1628_CR273","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.jhep.2017.05.019","volume":"67","author":"Z Lu","year":"2017","unstructured":"Lu Z, Zuo B, Jing R, Gao X, Rao Q, Liu Z, Qi H, Guo H, Yin H. Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models. J Hepatol. 2017;67:739\u201348.","journal-title":"J Hepatol"},{"key":"1628_CR274","doi-asserted-by":"publisher","first-page":"2","DOI":"10.21037\/sci-2022-030","volume":"10","author":"S Meng","year":"2023","unstructured":"Meng S, Whitt AG, Stamp BF, Eaton JW, Li C, Yaddanapudi K. Exosome-based cancer vaccine for prevention of lung cancer. Stem Cell Investig. 2023;10:2.","journal-title":"Stem Cell Investig"},{"key":"1628_CR275","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1016\/j.apsb.2022.02.017","volume":"12","author":"M Zhou","year":"2022","unstructured":"Zhou M, Zuo Q, Huang Y, Li L. Immunogenic hydrogel toolkit disturbing residual tumor \u201cseeds\u201d and pre-metastatic \u201csoil\u201d for inhibition of postoperative tumor recurrence and metastasis. Acta Pharm Sin B. 2022;12:3383\u201397.","journal-title":"Acta Pharm Sin B"},{"key":"1628_CR276","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.5114\/aoms.2016.60509","volume":"13","author":"KA Rygiel","year":"2017","unstructured":"Rygiel KA, Drozd M, Bulas L. Care of cancer patients with liver and bone metastases - the place of pharmaceutical care in a balanced plan, focused on the patient\u2019s needs and goals. Arch Med Sci. 2017;13:1483\u201392.","journal-title":"Arch Med Sci"},{"key":"1628_CR277","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41551-019-0434-z","volume":"3","author":"J Wen","year":"2019","unstructured":"Wen J, Wu D, Qin M, Liu C, Wang L, Xu D, Vinters HV, Liu Y, Kranz E, Guan X, Sun G, Sun X, Lee Y, Martinez-Maza O, Widney D, Lu Y, Chen ISY, Kamata M. Sustained delivery and molecular targeting of a therapeutic monoclonal antibody to metastases in the central nervous system of mice. Nat Biomed Eng. 2019;3:706\u201316.","journal-title":"Nat Biomed Eng"},{"key":"1628_CR278","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jconrel.2018.04.053","volume":"292","author":"L Mei","year":"2018","unstructured":"Mei L, Rao J, Liu Y, Li M, Zhang Z, He Q. Effective treatment of the primary tumor and lymph node metastasis by polymeric micelles with variable particle sizes. J Control Release. 2018;292:67\u201377.","journal-title":"J Control Release"},{"key":"1628_CR279","doi-asserted-by":"publisher","first-page":"8648","DOI":"10.1021\/acsnano.9b03472","volume":"13","author":"J Liu","year":"2019","unstructured":"Liu J, Li HJ, Luo YL, Xu CF, Du XJ, Du JZ, Wang J. Enhanced primary tumor penetration facilitates nanoparticle draining into lymph nodes after systemic injection for tumor metastasis inhibition. ACS Nano. 2019;13:8648\u201358.","journal-title":"ACS Nano"},{"key":"1628_CR280","doi-asserted-by":"publisher","first-page":"19441","DOI":"10.1021\/acsnano.3c08064","volume":"17","author":"Z Tian","year":"2023","unstructured":"Tian Z, Hu Q, Sun Z, Wang N, He H, Tang Z, Chen W. A booster for radiofrequency ablation: advanced adjuvant therapy via in situ nanovaccine synergized with anti-programmed death ligand 1 immunotherapy for systemically constraining hepatocellular carcinoma. ACS Nano. 2023;17:19441\u201358.","journal-title":"ACS Nano"},{"key":"1628_CR281","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1172\/JCI81137","volume":"126","author":"JM Pitt","year":"2016","unstructured":"Pitt JM, Andr\u00e9 F, Amigorena S, Soria JC, Eggermont A, Kroemer G, Zitvogel L. Dendritic cell-derived exosomes for cancer therapy. J Clin Investig. 2016;126:1224\u201332.","journal-title":"J Clin Investig"},{"key":"1628_CR282","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s00262-020-02496-w","volume":"69","author":"QT Wang","year":"2020","unstructured":"Wang QT, Nie Y, Sun SN, Lin T, Han RJ, Jiang J, Li Z, Li JQ, Xiao YP, Fan YY, Yuan XH, Zhang H, Zhao BB, Zeng M, Li SY, Liao HX, Zhang J, He YW. Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients. Cancer Immunol, Immunotherapy\u202f: CII. 2020;69:1375\u201387.","journal-title":"Cancer Immunol, Immunotherapy : CII"},{"key":"1628_CR283","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1158\/1078-0432.CCR-21-2867","volume":"28","author":"JL Hu","year":"2022","unstructured":"Hu JL, Omofoye OA, Rudnick JD, Kim S, Tighiouart M, Phuphanich S, Wang H, Mazer M, Ganaway T, Chu RM, Patil CG, Black KL, Shiao SL, Wang R, Yu JS. A phase I study of autologous dendritic cell vaccine pulsed with allogeneic stem-like cell line lysate in patients with newly diagnosed or recurrent glioblastoma. Clinical Cancer Res\u202f: Off J Am Assoc Cancer Res. 2022;28:689\u201396.","journal-title":"Clinical Cancer Res : Off J Am Assoc Cancer Res"},{"key":"1628_CR284","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12865-020-0338-4","volume":"21","author":"J S\u00e1nchez Ram\u00edrez","year":"2020","unstructured":"S\u00e1nchez Ram\u00edrez J, Morera D\u00edaz Y, Bequet-Romero M, Hern\u00e1ndez-Bernal F, Mart\u00edn Bauta Y, Selman-Housein Bernal KH, de la Torre Santos AV, P\u00e9rez de la Iglesia M, Trimi\u00f1o Lorenzo L, Ayala Avila M. Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program. BMC Immunol. 2020;21:12.","journal-title":"BMC Immunol"},{"key":"1628_CR285","doi-asserted-by":"publisher","first-page":"e003238","DOI":"10.1136\/jitc-2021-003238","volume":"9","author":"PJ DeMaria","year":"2021","unstructured":"DeMaria PJ, Lee-Wisdom K, Donahue RN, Madan RA, Karzai F, Schwab A, Palena C, Jochems C, Floudas C, Strauss J, Mart\u00e9 JL, Redman JM, Dombi E, Widemann B, Korchin B, Adams T, Pico-Navarro C, Heery C, Schlom J, Bilusic M. Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer. J Immunotherapy Cancer. 2021;9:e003238.","journal-title":"J Immunotherapy Cancer"},{"key":"1628_CR286","doi-asserted-by":"publisher","first-page":"e003238","DOI":"10.1136\/jitc-2021-003238","volume":"9","author":"PJ DeMaria","year":"2021","unstructured":"DeMaria PJ, Lee-Wisdom K, Donahue RN, Madan RA, Karzai F, Schwab A, Palena C, Jochems C, Floudas C, Strauss J, Marte JL, Redman JM, Dombi E, Widemann B, Korchin B, Adams T, Pico-Navarro C, Heery C, Schlom J, Bilusic M. Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer. J Immunotherapy Cancer. 2021;9:e003238\u2013e003238.","journal-title":"J Immunotherapy Cancer"},{"key":"1628_CR287","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, Ceglia N, Guasp P, Chu A, Yu R, Chandra AK, Waters T, Ruan J, Amisaki M, Zebboudj A, Odgerel Z, Payne G, Derhovanessian E, Balachandran VP. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618:144\u201350.","journal-title":"Nature"},{"issue":"10427","key":"1628_CR288","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, Kim KB, McKean M, Long GV, Sullivan RJ, Faries M. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024;403(10427):632\u201344.","journal-title":"Lancet"},{"key":"1628_CR289","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13073-021-00940-9","volume":"13","author":"D Srikrishna","year":"2021","unstructured":"Srikrishna D, Sachsenmeier K. We need to bring R0 < 1 to treat cancer too. Genome medicine. 2021;13:120.","journal-title":"Genome medicine"},{"key":"1628_CR290","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41565-022-01098-0","volume":"17","author":"C Liu","year":"2022","unstructured":"Liu C, Liu X, Xiang X, Pang X, Chen S, Zhang Y, Ren E, Zhang L, Liu X, Lv P, Wang X, Luo W, Xia N, Chen X, Liu G. A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy. Nat Nanotechnol. 2022;17:531\u201340.","journal-title":"Nat Nanotechnol"},{"key":"1628_CR291","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jamaoncol.2016.6007","volume":"3","author":"LG Salazar","year":"2017","unstructured":"Salazar LG, Lu H, Reichow JL, Childs JS, Coveler AL, Higgins DM, Waisman J, Allison KH, Dang Y, Disis ML. Topical imiquimod plus nab-paclitaxel for breast cancer cutaneous metastases: a phase 2 clinical trial. JAMA Oncol. 2017;3:969\u201373.","journal-title":"JAMA Oncol"},{"key":"1628_CR292","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.annonc.2019.12.002","volume":"31","author":"M Alyamani","year":"2020","unstructured":"Alyamani M, Li J, Patel M, Taylor S, Nakamura F, Berk M, Przybycin C, Posadas EM, Madan RA, Gulley JL, Rini B, Garcia JA, Klein EA, Sharifi N. Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure. Annals Oncol\u202f: Off J European Soc Med Oncol. 2020;31:369\u201376.","journal-title":"Annals Oncol : Off J European Soc Med Oncol"},{"key":"1628_CR293","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/oncolo\/oyac100","volume":"27","author":"KT Schmidt","year":"2022","unstructured":"Schmidt KT, Karzai F, Bilusic M, Cordes LM, Chau CH, Peer CJ, Wroblewski S, Huitema ADR, Schellens JHM, Gulley JL, Dahut WL, Figg WD, Madan RA. A single-arm phase II study combining NLG207, a nanoparticle camptothecin, with enzalutamide in advanced metastatic castration-resistant prostate cancer post-enzalutamide. Oncologist. 2022;27:718-e694.","journal-title":"Oncologist"},{"key":"1628_CR294","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1021\/acsnano.2c08880","volume":"17","author":"N Ma","year":"2023","unstructured":"Ma N, Chen Z, Liu G, Yue Y, Li Y, Cheng K, Ma X, Feng Q, Liang J, Zhang T, Gao X, Wang X, Guo X, Zhu F, Nie G, Zhao X. Normalizing the immune macroenvironment via debulking surgery to strengthen tumor nanovaccine efficacy and eliminate metastasis. ACS Nano. 2023;17:437\u201352.","journal-title":"ACS Nano"},{"issue":"1","key":"1628_CR295","doi-asserted-by":"publisher","first-page":"e2203298","DOI":"10.1002\/advs.202203298","volume":"10","author":"Q Liu","year":"2022","unstructured":"Liu Q, Chu Y, Shao J, Hanqing Qian J, Yang HS, Cen L, Tian M, Qiuping X, Chen F, Yang Y, Wang W, Wang K, Lixia Y, Wei J, Liu B. Benefits of an immunogenic personalized neoantigen nanovaccine in patients with high\u2010risk gastric\/gastroesophageal junction cancer. Adv Sci. 2022;10(1):e2203298. https:\/\/doi.org\/10.1002\/advs.202203298.","journal-title":"Adv Sci"},{"key":"1628_CR296","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.114107","volume":"182","author":"Z Meng","year":"2022","unstructured":"Meng Z, Zhang Y, Zhou X, Ji J, Liu Z. Nanovaccines with cell-derived components for cancer immunotherapy. Adv Drug Deliv Rev. 2022;182: 114107.","journal-title":"Adv Drug Deliv Rev"},{"key":"1628_CR297","doi-asserted-by":"publisher","first-page":"18818","DOI":"10.1021\/acsnano.3c03274","volume":"17","author":"G Chen","year":"2023","unstructured":"Chen G, Li X, Li R, Wu K, Lei Z, Dai R, Roche K, Wang AZ, Min Y. Chemotherapy-induced neoantigen nanovaccines enhance checkpoint blockade cancer immunotherapy. ACS Nano. 2023;17:18818\u201331.","journal-title":"ACS Nano"},{"key":"1628_CR298","doi-asserted-by":"publisher","first-page":"6477","DOI":"10.1021\/acsnano.8b09613","volume":"13","author":"F Fontana","year":"2019","unstructured":"Fontana F, Fusciello M, Groeneveldt C, Capasso C, Chiaro J, Feola S, Liu Z, Makila EM, Salonen JJ, Hirvonen JT, Cerullo V, Santos HA. Biohybrid vaccines for improved treatment of aggressive melanoma with checkpoint inhibitor. ACS Nano. 2019;13:6477\u201390.","journal-title":"ACS Nano"},{"key":"1628_CR299","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/IJN.S346044","volume":"17","author":"P Zhao","year":"2022","unstructured":"Zhao P, Xu Y, Ji W, Li L, Qiu L, Zhou S, Qian Z, Zhang H. Hybrid membrane nanovaccines combined with immune checkpoint blockade to enhance cancer immunotherapy. Int J Nanomedicine. 2022;17:73\u201389.","journal-title":"Int J Nanomedicine"},{"key":"1628_CR300","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","volume":"24","author":"LH Butterfield","year":"2024","unstructured":"Butterfield LH, Najjar YG. Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nat Rev Immunol. 2024;24:399\u2013416.","journal-title":"Nat Rev Immunol"},{"issue":"24","key":"1628_CR301","doi-asserted-by":"publisher","first-page":"17134","DOI":"10.3390\/ijms242417134","volume":"24","author":"MA Picon","year":"2023","unstructured":"Picon MA, Wang L, Da Fonseca Ferreira A, Dong C, Marzouka GR. Extracellular vesicles as delivery systems in disease therapy. Int J Mol Sci. 2023;24(24):17134.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1628_CR302","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3390\/vaccines12010049","volume":"12","author":"Z Weng","year":"2023","unstructured":"Weng Z, Yang N, Shi S, Xu Z, Chen Z, Liang C, Zhang X, Du X. Outer membrane vesicles from acinetobacter baumannii: biogenesis, functions, and vaccine application. Vaccines. 2023;12(1):49.","journal-title":"Vaccines"},{"key":"1628_CR303","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.1038\/s41467-023-40207-y","volume":"14","author":"J Meng","year":"2023","unstructured":"Meng J, Lv Y, Bao W, Meng Z, Wang S, Wu Y, Li S, Jiao Z, Tian Z, Ma G, Wei W. Generation of whole tumor cell vaccine for on-demand manipulation of immune responses against cancer under near-infrared laser irradiation. Nat Commun. 2023;14:4505.","journal-title":"Nat Commun"},{"key":"1628_CR304","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1021\/acs.nanolett.0c04783","volume":"21","author":"P Xiao","year":"2021","unstructured":"Xiao P, Wang J, Zhao Z, Liu X, Sun X, Wang D, Li Y. Engineering nanoscale artificial antigen-presenting cells by metabolic dendritic cell labeling to potentiate cancer immunotherapy. Nano Lett. 2021;21:2094\u2013103.","journal-title":"Nano Lett"},{"key":"1628_CR305","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1172\/JCI67382","volume":"124","author":"JG Facciponte","year":"2014","unstructured":"Facciponte JG, Ugel S, De Sanctis F, Li C, Wang L, Nair G, Sehgal S, Raj A, Matthaiou E, Coukos G, Facciabene A. Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature. J Clin Invest. 2014;124:1497\u2013511.","journal-title":"J Clin Invest"},{"key":"1628_CR306","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12951-023-02273-8","volume":"22","author":"M Jin","year":"2024","unstructured":"Jin M, Huo D, Sun J, Hu J, Liu S, Zhan M, Zhang BZ, Huang JD. Enhancing immune responses of ESC-based TAA cancer vaccines with a novel OMV delivery system. J Nanobiotechnol. 2024;22:15.","journal-title":"J Nanobiotechnol"},{"key":"1628_CR307","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113556","volume":"42","author":"WJ Jin","year":"2023","unstructured":"Jin WJ, Jagodinsky JC, Vera JM, Clark PA, Zuleger CL, Erbe AK, Ong IM, Le T, Tetreault K, Berg T, Rakhmilevich AL, Kim K, Newton MA, Albertini MR, Sondel PM, Morris ZS. NK cells propagate T cell immunity following in situ tumor vaccination. Cell Rep. 2023;42: 113556.","journal-title":"Cell Rep"},{"key":"1628_CR308","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202108012","volume":"34","author":"J Li","year":"2022","unstructured":"Li J, Huang D, Cheng R, Figueiredo P, Fontana F, Correia A, Wang S, Liu Z, Kemell M, Torrieri G, M\u00e4kil\u00e4 EM, Salonen JJ, Hirvonen J, Gao Y, Li J, Luo Z, Santos HA, Xia B. Multifunctional biomimetic nanovaccines based on photothermal and weak-immunostimulatory nanoparticulate cores for the immunotherapy of solid tumors. Adv Mater. 2022;34: e2108012.","journal-title":"Adv Mater"},{"key":"1628_CR309","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115928","volume":"169","author":"SI Hung","year":"2023","unstructured":"Hung SI, Chu MT, Hou MM, Lee YS, Yang CK, Chu SY, Liu FY, Hsu HC, Pao SC, Teng YC, Chen CB, Chao A, Chung WH, Chang JW, Lai CH. Personalized neoantigen-based T cell therapy triggers cytotoxic lymphocytes expressing polyclonal TCR against metastatic ovarian cancer. Biomed Pharmacother. 2023;169: 115928.","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"1628_CR310","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007935","volume":"11","author":"JA Carter","year":"2023","unstructured":"Carter JA, Matta B, Battaglia J, Somerville C, Harris BD, LaPan M, Atwal GS, Barnes BJ. Identification of pan-cancer\/testis genes and validation of therapeutic targeting in triple-negative breast cancer: Lin28a-based and Siglece-based vaccination induces antitumor immunity and inhibits metastasis. J Immunotherapy Cancer. 2023;11(12): e007935.","journal-title":"J Immunotherapy Cancer"},{"key":"1628_CR311","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1158\/2326-6066.CIR-14-0058","volume":"2","author":"G Chen","year":"2014","unstructured":"Chen G, Gupta R, Petrik S, Laiko M, Leatherman JM, Asquith JM, Daphtary MM, Garrett-Mayer E, Davidson NE, Hirt K, Berg M, Uram JN, Dauses T, Fetting J, Duus EM, Atay-Rosenthal S, Ye X, Wolff AC, Stearns V, Emens LA. A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer. Cancer Immunol Res. 2014;2:949\u201361.","journal-title":"Cancer Immunol Res"},{"issue":"211","key":"1628_CR312","first-page":"219","volume":"1950","author":"BG Vincent","year":"2023","unstructured":"Vincent BG, File DM, McKinnon KP, Moore DT, Frelinger JA, Collins EJ, Ibrahim JG, Bixby L, Reisdorf S, Laurie SJ, Park YA, Anders CK, Collichio FA, Muss HB, Carey LA, van Deventer HW, Dees EC, Serody JS. Efficacy of a dual-epitope dendritic cell vaccine as part of combined immunotherapy for HER2-expressing breast tumors. J Immunol Baltimore Md. 2023;1950(211):219\u201328.","journal-title":"J Immunol Baltimore Md"},{"key":"1628_CR313","doi-asserted-by":"publisher","first-page":"3931","DOI":"10.1245\/s10434-014-3844-x","volume":"21","author":"L Zheng","year":"2014","unstructured":"Zheng L, Edil BH, Soares KC, El-Shami K, Uram JN, Judkins C, Zhang Z, Onners B, Laheru D, Pardoll D, Jaffee EM, Schulick RD. A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte-macrophage colony stimulating factor-producing bystander cell line in patients with metastatic colorectal cancer. Ann Surg Oncol. 2014;21:3931\u20137.","journal-title":"Ann Surg Oncol"},{"key":"1628_CR314","doi-asserted-by":"publisher","first-page":"5493","DOI":"10.1158\/1078-0432.CCR-18-2992","volume":"25","author":"DT Le","year":"2019","unstructured":"Le DT, Picozzi VJ, Ko AH, Wainberg ZA, Kindler H, Wang-Gillam A, Oberstein P, Morse MA, Zeh HJ 3rd, Weekes C, Reid T, Borazanci E, Crocenzi T, LoConte NK, Musher B, Laheru D, Murphy A, Whiting C, Nair N, Jaffee EM. Results from a phase IIb, randomized, multicenter study of GVAX pancreas and CRS-207 compared with chemotherapy in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE Study). Clinical Cancer Res: Off J Am Assoc Cancer Res. 2019;25:5493\u2013502.","journal-title":"Clinical Cancer Res: Off J Am Assoc Cancer Res"},{"key":"1628_CR315","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1479-5876-10-28","volume":"10","author":"E Hamilton","year":"2012","unstructured":"Hamilton E, Blackwell K, Hobeika AC, Clay TM, Broadwater G, Ren XR, Chen W, Castro H, Lehmann F, Spector N, Wei J, Osada T, Lyerly HK, Morse MA. Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]. J Transl Med. 2012;10:28.","journal-title":"J Transl Med"},{"key":"1628_CR316","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1200\/JCO.22.00096","volume":"41","author":"O Adot\u00e9vi","year":"2023","unstructured":"Adot\u00e9vi O, Vernerey D, Jacoulet P, Meurisse A, Laheurte C, Almotlak H, Jacquin M, Kaulek V, Boullerot L, Malfroy M, Orillard E, Eberst G, Lagrange A, Favier L, Gainet-Brun M, Doucet L, Teixeira L, Ghrieb Z, Clairet AL, Westeel V. Safety, immunogenicity, and 1-year efficacy of universal cancer peptide-based vaccine in patients with refractory advanced non-small-cell lung cancer: a phase Ib\/Phase IIa de-escalation study. J Clin Oncol\u202f: Off J Am Soc Clin Oncol. 2023;41:373\u201384.","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"1","key":"1628_CR317","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1512329","volume":"8","author":"JG Pol","year":"2019","unstructured":"Pol JG, Acuna SA, Yadollahi B, Tang N, Stephenson KB, Atherton MJ, Hanwell D, El-Warrak A, Goldstein A, Moloo B, Turner PV. Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials. Oncoimmunology. 2019;8(1): e1512329.","journal-title":"Oncoimmunology"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01628-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-024-01628-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01628-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T06:09:17Z","timestamp":1732774157000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-024-01628-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":317,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1628"],"URL":"https:\/\/doi.org\/10.1186\/s13045-024-01628-4","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"assertion":[{"value":"11 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"115"}}